{"text": "Similar observations were made for response rate ( not shown ) .Thirty percent of the patients in the present study received more than 6 cycles of trabectedin , which underlines an acceptable toxicity profile allowing prolonged treatment .", "label": "", "metadata": {}, "score": "34.802628"}
{"text": "Nevertheless , a CBR of 34 % was achieved , including long - lasting disease stabilization in subtypes such as rhabdomyosarcoma .In this non - trial setting , port - associated complications were more frequent ( 14 % ) with trabectedin compared to other continuous infusion protocols administered at our outpatient therapy center .", "label": "", "metadata": {}, "score": "36.25596"}
{"text": "CONCLUSIONS : Sorafenib demonstrated activity as a second- or third - line treatment in terms of PFS at 4 months with some unprecedented long - lasting responses .", "label": "", "metadata": {}, "score": "36.37408"}
{"text": "The median PFS under treatment with trabectedin was 2.1 months in the overall population .Notably , long lasting remissions were even observed in 7th - line treatment .", "label": "", "metadata": {}, "score": "37.280525"}
{"text": "In this study , we retrospectively analyzed 25 patients who had been treated with trabectedin at our institution between 2007 and 2010 .Response assessed by conventional RECIST criteria was low , with only one patient achieving a partial remission ( PR ) and 10 stable disease ( SD ) after three cycles of treatment .", "label": "", "metadata": {}, "score": "38.740532"}
{"text": "Plasma samples were obtained to assess PK profiles .Results : The MTD of trabectedin was 1.1 mg / m2 .Drug - related grade 3 and 4 toxic effects were neutropenia ( 31 % ) and elevated transaminases ( 31 % ) .", "label": "", "metadata": {}, "score": "39.5466"}
{"text": "Because four of the first six patients experienced DLT - defining neutropenia during cycle 1 , all subsequent patients received primary prophylactic G - CSF .", "label": "", "metadata": {}, "score": "39.681564"}
{"text": "Only limited data are available in other sarcoma subtypes , heavily pretreated and elderly patients .We retrospectively analyzed 101 consecutive sarcoma patients treated with trabectedin at our center .", "label": "", "metadata": {}, "score": "39.726036"}
{"text": "The majority of the included prospective studies were Phase II trials with a variety of chemotherapeutic regimens evaluated across these studies .Response , PFS , DOR , TTP , OS , and safety were the most commonly assessed outcomes in the included studies .", "label": "", "metadata": {}, "score": "39.836426"}
{"text": "The RCT by Verweij and colleagues was excluded from the review as the study included patients with GIST [ 93 ] .In the study by Sleijfer and colleagues , the type of prior therapy was not reported [ 94 ] , while in the study by Bay and colleagues no sub - group data for patients receiving first - line and later - lines therapies was provided [ 95 ] .", "label": "", "metadata": {}, "score": "40.211945"}
{"text": "This series represents therefore a selected subgroup of patients treated mostly in reference centres for sarcoma , and in experienced centres regarding trabectedin usage .Among the 11 centres participating to the study , 5 had participated to the phase II EORTC trial , reflecting the experience of the centres with this agent .", "label": "", "metadata": {}, "score": "40.223953"}
{"text": "Plasma samples were collected for pharmacokinetic analysis .Results Fifteen patients received 1 of 3 dose levels of trabectedin .Dose - limiting toxicity occurred in two of three patients at 1.5 mg / m2 : 1 had a grade 3 increase in creatine phosphokinase and grade 3 anorexia , and the other had grade 4 platelet count decreased .", "label": "", "metadata": {}, "score": "40.263527"}
{"text": "With a median follow - up of 64 months after initiation of trabectedin treatment , the median PFS was 3.6 months , with a 6-months PFS rate of 39 % .", "label": "", "metadata": {}, "score": "40.301285"}
{"text": "Evidence review : .Five phase I studies in patients with solid tumors , all of which include sarcoma patients , evaluating the dosing and toxicity of trabectedin were performed with efficacy being evaluated as a secondary endpoint .", "label": "", "metadata": {}, "score": "40.443966"}
{"text": "All patients had previously received anthracyclines , and 23 out of 27 patients had received taxanes .Of 21 patients with measurable disease , three confirmed partial responses , one unconfirmed partial response and two minor responses ( 49 and 32 % tumour shrinkage ) were observed ; six patients had stable disease .", "label": "", "metadata": {}, "score": "40.49884"}
{"text": "Results .Trabectedin was given in first , second , third or fourth line in metastatic phase in 6 % , 37 % , 33 % and 23 % of patients respectively .", "label": "", "metadata": {}, "score": "40.714485"}
{"text": "Conclusion : Trabectedin combined with PLD is generally well tolerated at therapeutic doses of both drugs in pretreated patients with diverse tumor types and appears to provide clinical benefit .", "label": "", "metadata": {}, "score": "40.87667"}
{"text": "The primary endpoint was to determine the maximum tolerated dose .Results : Five patients were included in the study .Two patients were treated on dose level 1 comprising trabectedin 0.9 mg / m2 on day 1 and gemcitabine 700 mg / m2 on days 1 + 8 , every 3 weeks .", "label": "", "metadata": {}, "score": "41.107857"}
{"text": "It inversely correlated with expression of cyclin D1 and Ki-67 .Conclusions : By demonstrating its relationship with clinical outcome , we propose evaluation of miR-34a at diagnosis of EWS patients to allow early risk stratification .", "label": "", "metadata": {}, "score": "41.504894"}
{"text": "An exhaustive retrospective study collecting the information on all patients treated with trabectedin since its approval could be very helpful to describe the outcome of patient populations in low volume centres .", "label": "", "metadata": {}, "score": "41.747765"}
{"text": "As maintenance treatment , good responders ( GR ) received nine cycles of VACAc - IE regimen .PRs received three cycles of VAC - IE , mobilizing cycle with CE and HDT with Busulfan and Melphalan with stem cell support .", "label": "", "metadata": {}, "score": "42.844223"}
{"text": "Follow - up was calculated from course 1 of trabectedin .Progression - free survival ( PFS ) was defined as the interval between the date of the first trabectedin cycle and the date of disease progression , death , or last follow - up contact .", "label": "", "metadata": {}, "score": "42.91983"}
{"text": "Across the RCTs , pazopanib over placebo , gemcitabine - dacarbazine over dacarbazine , and trabectedin 3-weekly over weekly regimen clearly demonstrated a PFS advantage in the second- and later - line treatment of advanced STS .", "label": "", "metadata": {}, "score": "42.95234"}
{"text": "A regimen of bortezomib , 1.3 mg / m2 on days 1 , 4 , 8 , and 11 with PLD , 30 mg / m2 , on day 4 of a 21-day cycle , was safe in this study , and merits further investigation .", "label": "", "metadata": {}, "score": "43.092155"}
{"text": "Investigator - reviewed PFS yielded similar results ( Fig 3A ) .At the time of data cutoff , inves- tigators had observed 238 PFS events , with a median PFS of 11.1 monthsforafatiniband6.7monthsforchemotherapy(HR,0.49;95 % CI,0.37to0.65;P ?", "label": "", "metadata": {}, "score": "43.375465"}
{"text": "A phase II study of afatinib in EGFR mutation - positive lung adenocarcinoma demonstrated high response rates and progression - free survival ( PFS ) .", "label": "", "metadata": {}, "score": "43.702744"}
{"text": "Approximately 650 patients will be randomly assigned to 1 of the treatment arms ( DOXIL and DOXIL + trabectedin ) over 2 years .At the time of randomization , patients will be stratified on the basis of platinum sensitivity of disease ( sensitive or resistant ) and baseline Eastern Cooperative Oncology Group performance status score ( 0 to 1 or 2 .", "label": "", "metadata": {}, "score": "43.793304"}
{"text": "Trabectedin was the only drug that led to a radiological response in this patient with synovial sarcoma , despite being administered at 75 % of the standard dose because of dose - limiting nausea and vomiting , in line with more recent data demonstrating activity in translocated sarcomas .", "label": "", "metadata": {}, "score": "43.81993"}
{"text": "These agents were also among those identified as potentially active second - line treatments in a recent analysis of Phase II studies by Penel and colleagues [ 91 ] .", "label": "", "metadata": {}, "score": "44.062813"}
{"text": "The present study assessed the activity and feasibility of trabectedin in women with advanced breast cancer previously treated with conventional therapies .Patients with advanced disease previously treated with at least one but not more than two regimens that included taxanes or anthracyclines as palliative therapy were eligible .", "label": "", "metadata": {}, "score": "44.18673"}
{"text": "CPT-11 was administered intravenously on days 1 and 15 , at a dose of 50 mg / m2 on both days .Results .During the period from April 2010 to March 2013 , three patients were enrolled for each level .", "label": "", "metadata": {}, "score": "44.19551"}
{"text": "Two - year actuarial lesion local control and overall survival were 85.9 % and 66.4 % , respectively .No G3 or greater acute and late toxicities were observed .", "label": "", "metadata": {}, "score": "44.202827"}
{"text": "The inclusion criteria were the same than those of the EORTC trial , with the exception that all lines were allowed .Not all patients could be retrospectively collected .", "label": "", "metadata": {}, "score": "44.221497"}
{"text": "Myelosuppression was managed with dose reductions and growth factor support .Grade 3 febrile neutropenia was observed in 2 patients ( 5.1 % ) .Non - hematologic adverse events occurred at the expected frequency and grade for each drug alone , with no unexpected or cumulative toxicities .", "label": "", "metadata": {}, "score": "44.386597"}
{"text": "Detailed side - effects of trabectedin treatment were not collected in this retrospective study .Only toxicity leading to hospitalization was documented and remained limited , affecting only 17 % of patients .", "label": "", "metadata": {}, "score": "44.57872"}
{"text": "Intheprimary Table 1 .Patient Demographics and Clinical Characteristics Characteristic Afatinib ( n ?230 )Cisplatin Plus Pemetrexed ( n ? 115 )No . %", "label": "", "metadata": {}, "score": "44.582375"}
{"text": "PubMed View Article .Demetri GD , et al .: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma and leiomyosarcoma after failure of prior antharcyclines or ifosfamide : results of a randomized phase II study of two different schedules .", "label": "", "metadata": {}, "score": "44.670044"}
{"text": "The study by van Oosterom and colleagues evaluating two different ifosfamide regimens provided no subgroup efficacy data including OS , TTP , PFS , and response duration specifically for patients previously treated in an advanced setting [ 29 ] .", "label": "", "metadata": {}, "score": "44.70538"}
{"text": "Results .A total of 37 patients with 4 median prior therapies were treated .Frequent grade 1 - 2 toxicities included fatigue , nausea , thrombocytopenia , anemia , neutropenia , constipation , myalgias , and peripheral neuropathy .", "label": "", "metadata": {}, "score": "44.75191"}
{"text": "The number of lines of chemotherapy administered before trabectedin also correlated significantly with longer PFS in the Cox model , but not for OS .Conversely , retroperitoneal location was were associated with a improved survival , possibly because of the low grade and loco - regional behavior ; most are liposarcomas , a subset associated with a better outcome in large retrospective datasets in the present series as well [ 2 ] .", "label": "", "metadata": {}, "score": "44.901688"}
{"text": "The number of patients randomised across all RCTs was greater than 50 , except for the study by Pacey and colleagues that randomised five patients [ 28 ] .", "label": "", "metadata": {}, "score": "44.90486"}
{"text": "PubMed View Article .Blay JY , von Mehren M , Samuels BL , et al .: Phase I combination study of trabectedin and doxorubicin in patients with soft - tissue sarcoma .", "label": "", "metadata": {}, "score": "44.975582"}
{"text": "This is a more heavily pretreated patient population than that of the EORTC trials .Despite of this , the response rate ( 10 % ) , stable disease rate ( 39 % ) , PFS ( median 3.6 months ) and OS ( median 16.1 months ) were comparable to those observed with trabectedin in the phase II trials . 2 ) histological classifications and inclusion criteria varied considerably between the 2 series ; for instance , GIST were mixed amongst leiomyosarcoma in the former series .", "label": "", "metadata": {}, "score": "45.03633"}
{"text": "No disease progression was reported .Neoadjuvant trabectedin was usually well tolerated , with a safety profile similar to that described in patients with soft tissue sarcoma or other tumor types .", "label": "", "metadata": {}, "score": "45.1368"}
{"text": "Transient and noncumulative transaminitis was observed in most of the patients .The pharmacokinetic profile of trabectedin in this patient 's population is in line with the overall data available with this schedule .", "label": "", "metadata": {}, "score": "45.137768"}
{"text": "This nonrandomized phase II study used a Simon two - stage design .PFS and OS at 95 % confidence intervals ( 95 % CIs ) were calculated by the Kaplan - Meier method .", "label": "", "metadata": {}, "score": "45.147934"}
{"text": "[ Time Frame : From first treatment through September 27 , 2010 ] .Progression Free Survival ( PFS ) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors ( RECIST 1.1 )", "label": "", "metadata": {}, "score": "45.275738"}
{"text": "In this study , we retrospectively analyzed 25 patients who had been treated with trabectedin at our institution between 2007 and 2010 .The majority ( 72 % ) had been heavily pre - treated with \u00b32 previous lines of chemotherapy .", "label": "", "metadata": {}, "score": "45.392513"}
{"text": "Solca F , Dahl C , Zoephel A , et al : Target binding properties and cellular activity of afatinib ( BIBW 2992 ) , an irreversible ErbB family blocker .", "label": "", "metadata": {}, "score": "45.414894"}
{"text": "Treatment - Related AEs ?AE Afatinib ( n ?229)Cisplatin Plus Pemetrexed ( n ? 111 )All Grades ?Grade 3All Grades ?Grade 3 No . %", "label": "", "metadata": {}, "score": "45.42297"}
{"text": "Seven patients maintained stable disease after two cycles .Gemcitabine and trabectedin pharmacokinetics were not altered substantially with concomitant administration .Conclusions .Given the lack of pharmacokinetic interaction and potential efficacy of trabectedin and gemcitabine combination therapy , further study is warranted with alternate schedules .", "label": "", "metadata": {}, "score": "45.519737"}
{"text": "PubMed View Article .Laverdiere C , Kolb EA , Supko JG , et al .: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma .", "label": "", "metadata": {}, "score": "45.758305"}
{"text": "According to these results , trabectedin was approved in September 2007 in the European Union for patients with advanced STS after failure of anthracyclins or ifosfamide or for those who are unsuited to receive such agents .", "label": "", "metadata": {}, "score": "45.907234"}
{"text": "This study recruited a mixed population of patients previously treated in an adjuvant or advanced setting , with limited subgroup data for the patients previously treated in the advanced setting [ 29 ] .", "label": "", "metadata": {}, "score": "45.952682"}
{"text": "Based on this review , the following regimens have demonstrated a PFS advantage : pazopanib over placebo , trabectedin 3-weekly over weekly schedule , and the combination of gemcitabine plus dacarbazine over dacarbazine alone .", "label": "", "metadata": {}, "score": "45.994617"}
{"text": "Trabectedin can induce response and tumour control in previously treated advanced breast cancer , with manageable toxicity , thus warranting further development as a single agent or in combination regimens .", "label": "", "metadata": {}, "score": "46.24038"}
{"text": "Current research focuses on the identification of predictive factors for patients treated with trabectedin , as well as the development of other combinations .PMCID : PMC3004573 PMID : 21188115 .", "label": "", "metadata": {}, "score": "46.29813"}
{"text": "J Clin Oncol .[PubMed ] .Chawla S , Blay JY , Schuetze S , Morris D , Ritch P , Le Cesne A , Casali PG , Perez J , Bayever E , Demetri G. Efficacy of second - line trabectedin in patients with advanced liposarcomas and leiomyosarcomas progressing despite prior conventional chemotherapy .", "label": "", "metadata": {}, "score": "46.43741"}
{"text": "2010 ; 21 : viii413 .Schoffski P , Wolter P , Clement P , Sciot R , De WI , Wozniak A , Stefan C , Dumez H. Trabectedin ( ET-743 ) : Evaluation of its use in advanced soft - tissue sarcoma .", "label": "", "metadata": {}, "score": "46.48938"}
{"text": "Grade 4 neutropenia was observed in two of three patients at level 4 .At level 4 , the antitumor effect was a partial response ( PR ) in two of the three patients and stable disease ( SD ) in one .", "label": "", "metadata": {}, "score": "46.49704"}
{"text": "This approach was used because there was insufficient data from controlled trials to conduct robust adjusted indirect treatment comparisons of PFS and OS [ 18 ] .", "label": "", "metadata": {}, "score": "46.542942"}
{"text": "[PubMed ] .Antman KH , Ryan L , Elias A , Sherman D , Grier HE .Response to ifosfamide and mesna : 124 previously treated patients with metastatic or unresectable sarcoma .", "label": "", "metadata": {}, "score": "46.712334"}
{"text": "PubMed View Article .Takebayashi Y , Pourquier P , Zimonjic DB , et al .: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription - coupled nucleotide - excision repair .", "label": "", "metadata": {}, "score": "46.804733"}
{"text": "For patients who relapse or develop resistance , other therapeutic options were limited before the availability of trabectedin [ 5 ] .For these patients , progression - free survival ( PFS ) and overall survival ( OS ) rarely exceed 6 months and 1 year respectively [ 5 ] .", "label": "", "metadata": {}, "score": "46.8405"}
{"text": "PubMed View Article .Damia G , Silvestri S , Carrassa L , et al .: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA - repair pathways .", "label": "", "metadata": {}, "score": "46.845016"}
{"text": "Results .Canfosfamide plus PLD combination therapy was administered at 960/50 mg / m2 , respectively .Thirty - nine patients received a median number of 4 cycles ( range 1.0 - 18.0 ) .", "label": "", "metadata": {}, "score": "46.857925"}
{"text": "The study by van Oosterom and colleagues included a mixed patient population of both first - line and second - line patients , with limited subgroup data for the patients treated in the second - line setting [ 29 ] .", "label": "", "metadata": {}, "score": "46.89023"}
{"text": "Effects on cell growth , signalling and cell cycle distribution were determined by flow cytometry assays .Mice harbouring xenografts of HER2/neu - amplified USC were treated with afatinib by gavage to determine the effect on tumour growth and overall survival .", "label": "", "metadata": {}, "score": "46.99205"}
{"text": "Efficacy / Activity outcomes across prospective non - randomised trials with sample size more than 10 .The only treatment that demonstrated a similar anti - tumour activity across different trials was trabectedin ( three studies ) .", "label": "", "metadata": {}, "score": "47.066357"}
{"text": "In vitro , trabectedin has shown potent cytotoxic activity against a variety of human STS cell lines , and antitumor activity against a variety of human xenografts , including sarcomas , with limited cross - resistance between trabectedin and other cytotoxic agents [ 11 - 15 ] .", "label": "", "metadata": {}, "score": "47.191406"}
{"text": "Results of treatment discontinuations across randomised controlled trials .Non - randomised studies .Trial characteristics .A summary of the 52 prospective non - randomised studies with sample size more than 10 [ 33 - 72 ] is presented in Table 5 .", "label": "", "metadata": {}, "score": "47.25717"}
{"text": "One patient refused local treatment , 242 ( 81 % ) underwent surgery [ with radiotherapy ( RT ) in 80 ] and 57 ( 19 % ) RT alone .", "label": "", "metadata": {}, "score": "47.26585"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : To evaluate neoadjuvant trabectedin ( 1.5 mg / m(2 ) 24-h i.v .infusion every 3 weeks ; three to six cycles ) in patients with locally advanced myoxid liposarcoma ( ML ) previously untreated with chemotherapy or radiation .", "label": "", "metadata": {}, "score": "47.58396"}
{"text": "Trabectedin was given at the standard schedule of 1.5 mg / m2 in 24 h continuous infusion every 21 days , as previously reported , with dose adaptations similar to those applied in the protocols [ 19 - 23 ] .", "label": "", "metadata": {}, "score": "47.584137"}
{"text": "The combination produced a statistically significant improvement in PFS versus bortezomib alone ; however , the actual PFS difference was less than 1 month , and the authors concluded that the clinical relevance of the PFS difference between the two cohorts was unclear .", "label": "", "metadata": {}, "score": "47.59134"}
{"text": "A NICE evaluation of trabectedin versus end - stage treatment based on the same model reported an ICER of \u00a3 56,985/QALY [41 ] .", "label": "", "metadata": {}, "score": "47.691628"}
{"text": "PubMed View Article .Garcia - Carbonero R , Supko J , Manola J , et al .: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy .", "label": "", "metadata": {}, "score": "48.088364"}
{"text": "Four phase II studies were performed in soft - tissue sarcoma patients with objective response rates ranging from 3.7 % to 17.1 % .Additionally , in two compassionate use trials , objective response rates between 14 % and 51 % were seen , the largest response resulting from a study specifically focusing on liposarcoma .", "label": "", "metadata": {}, "score": "48.12439"}
{"text": "Results .The review identified six RCTs ( one phase III and five phase II trials ) and 94 non - randomised studies .The non - randomised studies demonstrated heterogeneity in efficacy and safety results .", "label": "", "metadata": {}, "score": "48.13101"}
{"text": "Statistical and Regulatory Considerations The trial sponsor collected and analyzed the data ; the lead investigators had full access to the data .The sample size was specified assuming a hazard ratio(HR)of0.64,equatingtoanincreaseinmedianPFSfromanexpected7 monthsforchemotherapyto11monthsforafatinib .", "label": "", "metadata": {}, "score": "48.13875"}
{"text": "None of the RCTs included in the review were identified as being at a high risk of bias .Efficacy / activity results .Table 2 summarises the various efficacy / activity results observed across the included RCTs .", "label": "", "metadata": {}, "score": "48.16195"}
{"text": "Primary analysis .( A )Progression - free survival ( PFS ) by independent review for all randomly assigned patients .At the time of data cutoff for primary analysis of PFS , 45 patients ( 20 % ) in the afatinib arm and three patients ( 3 % ) in the chemotherapy arm were known to be alive and progression free .", "label": "", "metadata": {}, "score": "48.21917"}
{"text": "Trabectedin has shown promising single - agent activity in pretreated patients with soft tissue sarcoma , and ovarian and breast cancer , and combination with various other chemotherapeutic drugs seems feasible .", "label": "", "metadata": {}, "score": "48.318645"}
{"text": "Patients and methods : Specimens from 109 patients with non - metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy ( protocols ISG / SSGIII , EW-1 , EW-2 , EW - REN2 , EW - REN3 , EW - PILOT ) and 17 metastases were studied .", "label": "", "metadata": {}, "score": "48.325344"}
{"text": "All but six ( 73 % ) patients had previously received at least one chemotherapy regimen .Of the 86 chemotherapy cycles delivered , grade 3 and 4 neutropaenia occurred in 20 % with no cases of febrile neutropaenia .", "label": "", "metadata": {}, "score": "48.343086"}
{"text": "Conclusions : .Two different trabectedin schedules showed modest activity in metastatic CRPC .Further studies may require identification of predictive factors of response in prostate cancer .", "label": "", "metadata": {}, "score": "48.359833"}
{"text": "On days 1 , 8 , and 15 of a 28-day cycle , patients received gemcitabine ( starting dose , 800 mg / m2 ) followed by trabectedin ( starting dose , 0.3 mg / m2 ) .", "label": "", "metadata": {}, "score": "48.39146"}
{"text": "The STS201 randomized , open - label study was conducted in adult STS patients with unresectable / metastatic liposarcoma or leiomyosarcoma , after failure of prior conventional chemotherapy including anthracyclins and ifosfamidei .", "label": "", "metadata": {}, "score": "48.463463"}
{"text": "Possibly the best comparison can be obtained with the subsequent paper by Van Glabbeke et al . , reporting separately second line + patients .In this case , the median progression free rate is 2.3 months , and a 1 year PFR rate of 7 % in the whole series , and 12 % for the series of patients treated with \" active agents \" [ 5 ] .", "label": "", "metadata": {}, "score": "48.553764"}
{"text": "( A )Progression - free survival ( PFS ) by investigator review for all randomly assigned patients .( B ) Forest plot of subgroups of patients showing PFS by investigator review .", "label": "", "metadata": {}, "score": "48.617184"}
{"text": "Trabectedin is a potential therapeutic option for the management of soft - tissue sarcoma .It appears to have specific activity in a select group of histologies , most notably myxoid / round cell liposarcoma .", "label": "", "metadata": {}, "score": "49.0553"}
{"text": "PATIENTS AND METHODS In this phase III study , eligible patients with stage IIIB / IV lung adenocarcinoma were screened for EGFR mutations .The primary end point was PFS by independent review .", "label": "", "metadata": {}, "score": "49.09732"}
{"text": "There werenotreatment - relatedfataltoxicitiesinthechemotherapyarm .Pharmacokinetics Toobtainacomprehensivepictureofexposure , predoseplasma samples were taken on days 1 and 8 of cycle two and day 1 of cycle three .", "label": "", "metadata": {}, "score": "49.248665"}
{"text": "J Clin Oncol .[PubMed ] .Scheulen ME , Niederle N , Bremer K , Schutte J , Seeber S. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna : Results of a clinical phase II - study with 151 patients .", "label": "", "metadata": {}, "score": "49.263184"}
{"text": "PFS for all patients was 58 % at three months and 37 % at six months .Side effects , including neutropenia , elevation of liver transaminases / liver function tests , and nausea / vomiting , were usually mild and manageable .", "label": "", "metadata": {}, "score": "49.367348"}
{"text": "Treatment regimens , efficacy endpoints , and safety profiles were compared between the two combination therapies .Results .Ten studies evaluating 608 patients ( PLD - Carbo : 5 studies , 278 patients ; Gem - Carbo : 5 studies , 330 patients ) were identified .", "label": "", "metadata": {}, "score": "49.46703"}
{"text": "PubMed .Ryan DP , Supko JG , Eder JP , et al .: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-h continuous intravenous infusion in patients with solid malignancies .", "label": "", "metadata": {}, "score": "49.56987"}
{"text": "The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin - based therapies .", "label": "", "metadata": {}, "score": "49.624237"}
{"text": "Although a wide variety of doses and schedules was used in these trials , with cumulative dose per cycle ranging from 8 to 14 mg / m 2 , this did not have a clear impact on efficacy .", "label": "", "metadata": {}, "score": "49.667194"}
{"text": "Conclusions .The MTD of trabectedin in pediatric patients with refractory solid tumors is 1.5 mg / m2 IV over 24 hours every 21 days .", "label": "", "metadata": {}, "score": "49.76771"}
{"text": "Summary of various efficacy / activity outcomes observed across randomised controlled trials .Phase III trials .A summary of these minor differences in results between analyses can be found in Additional file 4 .", "label": "", "metadata": {}, "score": "49.787502"}
{"text": "Overall survival was however not significantly different than that of on patients without toxicity - related hospitalization .Because most toxicities do not lead to rehospitalisation , no formal conclusion can be proposed on a possible lack of correlation with therapeutic efficacy , considering also the limited number of patients in this series .", "label": "", "metadata": {}, "score": "49.87609"}
{"text": "These findings should be interpreted in view of the fact that the evidence comes from Phase II studies except for the pazopanib PALETTE study .The primary aim of Phase II trials is to evaluate if the intervention under investigation demonstrates clinical activity and is well tolerated , and hence , they do not provide a definitive answer regarding the clinical benefit of the intervention in question .", "label": "", "metadata": {}, "score": "50.121956"}
{"text": "Patients between the ages of 4 and 16 years old with refractory solid tumors received trabectedin as a 24-hour infusion every 21 days .", "label": "", "metadata": {}, "score": "50.137062"}
{"text": "Fifty - three percent of patients initially treated with dacarbazine monotherapy and 51 % of patients treated with the combination of gemcitabine and dacarbazine received post - study therapy comprising mainly gemcitabine - based regimens , trabectedin , and taxanes [ 20 , 21 ] .", "label": "", "metadata": {}, "score": "50.139927"}
{"text": "PFS and OS rates were estimated using the Kaplan - Meier method and were compared using the log - rank test .Univariate analyses included the following variables : age ; sex ; performance status ; grade ; histological subtype ; disease location , myxoid liposarcoma histology , translocation sarcoma , treatment line , hospitalization for toxicity and liver / lung metastases .", "label": "", "metadata": {}, "score": "50.140255"}
{"text": "A partial radiological response was achieved ; dosage was reduced to 1.1 mg / m2 because of mild asthenia , grade 3 neutropenia , grade 3 nausea and vomiting , and reversible transaminase elevation .", "label": "", "metadata": {}, "score": "50.26291"}
{"text": "Adverse events ( AEs ) , tumor response , and survival were assessed .Results .The MTD was trabectedin 1.1 mg / m2 and doxorubicin 60 mg / m2 .", "label": "", "metadata": {}, "score": "50.286392"}
{"text": "[PubMed ] .Antman KH , Montella D , Rosenbaum C , Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma .", "label": "", "metadata": {}, "score": "50.29467"}
{"text": "Patients in the trabectedin / PLD arm received subsequent chemotherapy at a later time ( median delay 2.5 months versus PLD arm ) .Conclusion : The superiority of trabectedin / PLD over single - agent PLD in OVA-301 can not be explained by differences in the extent or nature of subsequent therapies administered to these patients .", "label": "", "metadata": {}, "score": "50.35434"}
{"text": "The efficacy of trabectedin in compassionate use programs may be different from those obtained in clinical trials , because patients with less favorable clinical characteristics are included .", "label": "", "metadata": {}, "score": "50.385643"}
{"text": "The primary objective of this study was to evaluate progression - free survival , while secondary endpoints were response rates , duration of response , overall survival , toxicity leading to hospital rehospitalisation , description of the patient populations , impact of treatment duration on treatment efficacy .", "label": "", "metadata": {}, "score": "50.490654"}
{"text": "Any discrepancies between the reviewers were resolved by a third independent reviewer .The full - text publications of all citations of potential interest were then screened for inclusion by two reviewers ( SS and ST ) , with disagreements resolved by a third independent reviewer .", "label": "", "metadata": {}, "score": "50.510864"}
{"text": "Only one patient submitted to tumor - free margin enbloc resection had local recurrence and died 29 months after the treatment ( biopsy was performed by open approach ) , the other surviving continuously disease free at 17 to 193 months follow - up ( av .", "label": "", "metadata": {}, "score": "50.5565"}
{"text": "PubMed View Article .Garcia - Carbonero R , Supko JG , Maki RG , et al .: Ecteinascidin-743 ( ET-743 ) for chemotherapy - naive patients with advanced soft tissue sarcomas : multicentre phase II and pharmacokinetic study .", "label": "", "metadata": {}, "score": "50.688335"}
{"text": "We conclude that trabectedin is an effective and generally well tolerated treatment for STS even in a heavily pre - treated patient population .Methods .", "label": "", "metadata": {}, "score": "50.797012"}
{"text": "Efficacy results .Across the non - randomised evidence , there was heterogeneity in the efficacy results .For example , in nine studies assessing ifosfamide monotherapy , variable activity was observed in terms of response rate ( 4.8 % [ 76 ] to 62.5 % [ 81 ] )", "label": "", "metadata": {}, "score": "50.90767"}
{"text": "1 months in patients with EGFR - mutated non - small cell lung cancer ( Sequist et al , 2013 ) .The primary toxicities of the drug included diarrhoea and rash .", "label": "", "metadata": {}, "score": "50.91823"}
{"text": "A simple Case Report Form with 22 items was used to collect patients ' characteristics and outcome .Information has been collected on an excel spreadsheet , consolidated in an Excel database , and then analyzed using the SPSS 12.1 software by institutional data manager .", "label": "", "metadata": {}, "score": "50.937645"}
{"text": "PubMed View Article .Moore BM , Ii FCS , Wheelhouse RT , Hurley LH : Mechanism for the Catalytic Activation of eteinascidin 743 and Its Subsequent Alkylation of Guanine N2 .", "label": "", "metadata": {}, "score": "50.97084"}
{"text": "7459 , pp .224 - 227 , 2004 .View at Google Scholar \u00b7 View at Scopus . E. J. O. Soini , B. G. san Andr\u00e9s , and T. Joensuu , \" Trabectedin in the treatment of metastatic soft tissue sarcoma : cost - effectiveness , cost - utility and value of information , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "51.009056"}
{"text": "\"Clinical trials that were designed based on the aforementioned preclinical data showed an increase in progression - free survival from 6 . 9 to 11 .", "label": "", "metadata": {}, "score": "51.02581"}
{"text": "Eur Cytokine Netw .[PubMed ] .Holstein K , Welt HJ , Walter TA , Llossfeld DK .Salvage chemotherapy with dacarbazine or carboplatin / VP-16 of advanced soft tissue sarcoma pretreated with doxorubicin / ifosfamide .", "label": "", "metadata": {}, "score": "51.091568"}
{"text": "Accordingly , postprogression utility values for pazopanib and placebo were obtained by combining treatment group - specific estimates of the mean decrement in utility postprogression in PALETTE ( reflecting the period immediately following progression ) with an estimate of utility in the terminal phase of the disease .", "label": "", "metadata": {}, "score": "51.09457"}
{"text": "6.1 ( 5.5 to 6.9 ) .No statistical analysis provided for Progression Free Survival ( PFS ) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors ( RECIST 1.1 ) .", "label": "", "metadata": {}, "score": "51.135826"}
{"text": "PubMed View Article .Van Glabbeke M , Verweij J , Judson I , Nielsen OS : Progression - free rate as the principal end - point for phase II trials in soft - tissue sarcomas .", "label": "", "metadata": {}, "score": "51.161392"}
{"text": "Median PFS was 11.1 months for afatinib and 6.9 months for chemotherapy ( hazard ratio [ HR ] , 0.58 ; 95 % CI , 0.43 to 0.78 ; P ?", "label": "", "metadata": {}, "score": "51.406815"}
{"text": "RCTs .Study characteristics .The key patient and study design characteristics of the six included RCTs are presented in Table 1 .All included RCTs were Phase II trials , except for the PALETTE study , which was the only Phase III RCT [ 18 , 19 ] .", "label": "", "metadata": {}, "score": "51.513496"}
{"text": "Administered activities ranged from 150 ( 3 mCi / kg ) to 1140 MBq / kg ( 30 mCi / kg ) .Autologous hematopoietic stem cell infusion was carried out on day 14 after the ( 153)Sm - EDTMP infusion .", "label": "", "metadata": {}, "score": "51.533104"}
{"text": "Lacking similar data for trabectedin , ifosfamide , and gemcitabine plus docetaxel , the proportions of events resulting in hospitalization for these therapies were assumed to be the same as those for pazopanib .", "label": "", "metadata": {}, "score": "51.596855"}
{"text": "Conclusion .The combination of doxorubicin 60 mg / m2 followed by trabectedin 1.1 mg / m2 every 21 days is safe and active in patients with STS .", "label": "", "metadata": {}, "score": "51.687702"}
{"text": "No cardiac or kidney function injuries were present .Based on these clinical and laboratory features , our conclusive diagnosis was of rhabdomyolysis induced by trabectedin .", "label": "", "metadata": {}, "score": "51.706875"}
{"text": "We conclude that trabectedin is an effective and generally well tolerated treatment for STS even in a heavily pre - treated patient population .Schmitt T , Keller E , Dietrich S , Wuchter P , Ho AD , Egerer G. Trabectedin for Metastatic Soft Tissue Sarcoma : A Retrospective Single Center Analysis .", "label": "", "metadata": {}, "score": "51.752552"}
{"text": "Conclusion : The GISG-02 phase I study was stopped with the conclusion that the combination of gemcitabine and trabectedin is generally not recommended for the treatment of patients with advanced and/or metastatic leiomyosarcoma or liposarcoma .", "label": "", "metadata": {}, "score": "51.782475"}
{"text": "Model Description .A multistate model was used to estimate expected PFS , OS , lifetime costs of treatment of aSTS , and quality - adjusted life - years ( QALYs ) in patients who had received prior treatment with chemotherapy and who were assumed to receive pazopanib , placebo , or chemotherapy .", "label": "", "metadata": {}, "score": "51.88262"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable . \" In a previous report from treatment with doxycycline for four weeks did not significantly reduce folliculitis incidence induced by erlotinib , but did reduce its severity [ 16 ] ; nonetheless , this study was not published in a complete way .", "label": "", "metadata": {}, "score": "51.88996"}
{"text": "At level 4 , the start of the next course was postponed in two of three patients .In addition , one patient at level 4 experienced hemotoxicity that met the criteria for dose reduction in the next course .", "label": "", "metadata": {}, "score": "51.914856"}
{"text": "All the patients submitted to intralesional excision and to enbloc resection resulting in margin violation had the same prognosis , as died of the disease 10 to 63 months after the treatment .", "label": "", "metadata": {}, "score": "51.946846"}
{"text": "PubMed .Villalona - Calero MA , Eckhardt SG , Weiss G , et al .: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies .", "label": "", "metadata": {}, "score": "51.9899"}
{"text": "Four patients were treated in the period 1979 to 1982 .All were submitted to chemotherapy ( REA-2 ) and radiation therapy ( RT ) .", "label": "", "metadata": {}, "score": "52.12744"}
{"text": "This trial was not designed to formally demonstrate an overall survival advantage , and therefore , this finding needs to be confirmed by an appropriately designed Phase III trial .", "label": "", "metadata": {}, "score": "52.130714"}
{"text": "56 of 181 patients ( 31 % ) received 6 cycles or more .During the course of treatment , 30 ( 17 % ) of the patients had to be re - admitted for treatment - related adverse events .", "label": "", "metadata": {}, "score": "52.159416"}
{"text": "PubMed .Takahashi N , Li WW , Banerjee D , Scotto KW , Bertino JR : Sequence - dependent enhancement of cytotoxicity produced by ecteinascidin 743 ( ET-743 ) with doxorubicin or paclitaxel in soft tissue sarcoma cells .", "label": "", "metadata": {}, "score": "52.282867"}
{"text": "Su KY , Chen HY , Li KC , et al : Pretreatment epidermal growth factor receptor ( EGFR ) T790 M mutation predicts shorter EGFR tyrosine kinase in- hibitor response duration in patients with non - small- cell lung cancer .", "label": "", "metadata": {}, "score": "52.33776"}
{"text": "The level of evidence of drug interaction leading to the adverse event observed in our patient was 2 ( probable ) .Thus our case underlines the importance of understanding rare treatment - related toxicities such as trabectedin - induced rhabdomyolysis and the possible role of the drug - drug interactions in the pathogenesis of this rare side effect .", "label": "", "metadata": {}, "score": "52.421207"}
{"text": "Inclusion criteria for the retrospective study .These criteria were those from the EORTC trial [ 23 ] , the largest of the single - arm phase II studies with trabectedin .", "label": "", "metadata": {}, "score": "52.4619"}
{"text": "Overall , five ( 12 % ) patients achieved a partial response , and 34 ( 83 % ) maintained stable disease .Median progression - free survival was 9.2 months .", "label": "", "metadata": {}, "score": "52.516426"}
{"text": "We therefore conducted a phase I trial of bortezomib and pegylated liposomal doxorubicin ( PLD ) in patients with refractory solid tumors .Methods .Patients received bortezomib , 0.9 - 1.5 mg / m2 , on days 1 , 4 , 8 , and 11 of every 21-day cycle , along with PLD , 30 mg / m2 , on day 4 .", "label": "", "metadata": {}, "score": "52.57083"}
{"text": "An important accompaniment to PFS gains with a genotype- directedtherapeuticstrategyisimprovementinPROs.31Wedemon- strated clinically meaningful delays in worsening of lung cancer- related symptoms in afatinib - treated patients compared with those treatedwithchemotherapy .", "label": "", "metadata": {}, "score": "52.780125"}
{"text": "PubMed View Article .Martinez EJ , Corey EJ , Owa T : Antitumor activity- and gene expression - based profiling of ecteinascidin Et 743 and phthalascidin Pt 650 .", "label": "", "metadata": {}, "score": "52.786255"}
{"text": "Patients and methods : The study was opened in 1999 and closed to the enrollment in 2008 .The program consisted of intensive five - drug combination chemotherapy , surgery and/or radiotherapy as local treatment , and consolidation treatment with high - dose busulfan / melphalan plus autologous stem cell rescue and total - lung irradiation .", "label": "", "metadata": {}, "score": "52.833595"}
{"text": "R. Garcia - Carbonero , J. G. Supko , R. G. Maki et al . , \" Ecteinascidin-743 ( ET-743 ) for chemotherapy - naive patients with advanced soft tissue sarcomas : multicenter phase II and pharmacokinetic study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "52.88584"}
{"text": "PubMed View Article .Li WW , Takahashi N , Jhanwar S , et al .: Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents : identification of ecteinascidin-743 as a potent cytotoxic agent .", "label": "", "metadata": {}, "score": "53.022675"}
{"text": "This study aimed to comprehensively review available data on the activity and safety of interventions in second- or later - line treatment of advanced STS .", "label": "", "metadata": {}, "score": "53.026478"}
{"text": "All the patients were submitted to multiagent protocols of chemotherapy ( always ) and radiotherapy ( alternative to surgery or associated to ) .Surgery was performed in 17 cases both for functional purpose ( 7 cases : intralesional piecemeal excision ) both for curative purpose ( 10 cases : enbloc resection , resulting characterized by marginal / wide or intralesional margins ) .", "label": "", "metadata": {}, "score": "53.310036"}
{"text": "If disease progression has not occurred at treatment termination , then disease assessment will continue every 8 weeks until there is evidence of disease progression or death , or until the clinical data cutoff date , or until the start of first subsequent anticancer therapy , whichever is earlier .", "label": "", "metadata": {}, "score": "53.338272"}
{"text": "Moreover , the weekly schedule may be less convenient than the every 3 week schedule .It should be noted that trabectedin is not currently approved for use in sarcoma in all countries .", "label": "", "metadata": {}, "score": "53.40573"}
{"text": "Data regarding the efficacy of neratinib was determined using 4 HER2 amplified cell lines and 4 non - amplified cell lines with similar growth rates .", "label": "", "metadata": {}, "score": "53.423264"}
{"text": "PubMed View Article .Yovine A , Riofrio M , Blay J , et al .: Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients .", "label": "", "metadata": {}, "score": "53.53357"}
{"text": "Patients ' characteristics are described in Table 1 . 29 % had translocation - related sarcomas .At diagnosis , grade 3 , 2 and 1 STS represented 44 % , 28 % and 9 % of the tumors respectively .", "label": "", "metadata": {}, "score": "53.575485"}
{"text": "Although , the review also included 52 prospective non - randomised studies , these studies were small in terms of sample size with majority of studies including less than 50 patients .", "label": "", "metadata": {}, "score": "53.582405"}
{"text": "By multivariate Cox regression analysis , low miR-34a expression as well as nontotal necrosis and high levels of lactate dehydrogenase were all confirmed as independent risk factors associated with poor outcome .", "label": "", "metadata": {}, "score": "53.624382"}
{"text": "Progression Free Survival ( PFS ) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors ( RECIST 1.1 ) .Measure Description .", "label": "", "metadata": {}, "score": "53.67346"}
{"text": "Summaries of the efficacy results for interventions evaluated across non - randomised studies are presented in Table 6 .Safety results .Across the non - randomised studies identified in the review , haematological AEs were the most commonly reported AEs , particularly with therapies including docetaxel , gemcitabine , docetaxel plus gemcitabine , etoposide , carboplatin plus etoposide , cisplatin plus ifosfamide , and trabectedin .", "label": "", "metadata": {}, "score": "53.70256"}
{"text": "[PubMed ] .Buesa JM , Losa R , Fernandez A , Sierra M , Esteban E , Diaz A , Lopez - Pousa A , Fra J. Phase I clinical trial of fixed - dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma , with assessment of gemcitabine triphosphate accumulation .", "label": "", "metadata": {}, "score": "53.80533"}
{"text": "Quality assessment of RCTs was performed using a comprehensive critical appraisal tool based on the National Institute for Health and Clinical Excellence 's and Cochrane 's critical appraisal tool [ 14 , 15 ] .", "label": "", "metadata": {}, "score": "53.821384"}
{"text": "Approximately two - thirds of patients had relapsed multiple myeloma , with one - third having relapsed and refractory disease .Patients with bortezomib- and primary - refractory disease were excluded from the trial .", "label": "", "metadata": {}, "score": "53.85678"}
{"text": "An interim analysis of overall survival will be performed in conjunction with progression - free survival analysis during the study .Treatment will be continued until disease progression occurred or until patients experienced a confirmed complete response for at least 2 cycles .", "label": "", "metadata": {}, "score": "53.858223"}
{"text": "Expression of miR-34a and of some of its targets ( cyclin D1 , bcl-2 , SIRT1 and YY1 ) was evaluated by qRT - PCR using TaqMan MicroRNA Assays and/or by immunohistochemistry on tissue microarrays from the same patients .", "label": "", "metadata": {}, "score": "53.882256"}
{"text": "Among the seven patients who had neurological symptoms at the occurrence , just those with no metastasis and who underwent enbloc resection are alive .The current study seems to demonstrate that tumor - free margin enbloc resection provides better local control and longer survival , while the results after intralesional margin resection or piecemeal excision combined with chemotherapy and RT is less effective than chemotherapy and RT alone .", "label": "", "metadata": {}, "score": "53.890556"}
{"text": "PubMed .Delaloge S , Yovine A , Taamma A , et al .: Ecteinascidin-743 : a marine - derived compound in advanced , pretreated sarcoma patients - preliminary evidence of activity .", "label": "", "metadata": {}, "score": "53.93917"}
{"text": "Conclusions .In this compassionate use program , trabectedin yielded similar or better PFS and OS than in clinical trials .Maintenance treatment beyond 6 cycles was associated with an improved survival .", "label": "", "metadata": {}, "score": "54.046806"}
{"text": "Based on the above , the RD of CPT-11 was determined to be 80 mg / m2 .Conclusions .The results suggest that CPT-11/PLD combination therapy for recurrent ovarian cancer is a useful treatment method with a high response rate and manageable adverse reactions .", "label": "", "metadata": {}, "score": "54.059723"}
{"text": "PubMed View Article .Taamma A , Misset JL , Riofrio M , et al .: Phase I and pharmacokinetic study of ecteinascidin-743 , a new marine compound , administered as a 24-h continuous infusion in patients with solid tumors .", "label": "", "metadata": {}, "score": "54.145153"}
{"text": "ResultsA total of 1,269 patients were screened , and 345 were randomly assigned to treatment .The most common treatment - related adverse events were diarrhea , rash / acne , and stomatitis for afatinib and nausea , fatigue , and decreased appetite for chemotherapy .", "label": "", "metadata": {}, "score": "54.181255"}
{"text": "Pharmacokinetics ; Clinical trial phase I ; Soft tissue sarcoma ; Trabectedin ; Chromosomal translocation .This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration - resistant prostate cancer ( CRPC ) .", "label": "", "metadata": {}, "score": "54.28627"}
{"text": "We therefore conducted a secondary analysis in which we compared pazopanib with other widely used chemotherapies .In this analysis , pazopanib was estimated to be dominant ( i.e. , provides greater QALYs at a lower cost ) compared with trabectedin , ifosfamide , and gemcitabine plus docetaxel .", "label": "", "metadata": {}, "score": "54.293015"}
{"text": "Patients were randomly assigned to receive pre - emptive treatment with tetracycline 250 mg every 12 hours for 4 weeks or not .Reactive treatment in both groups included general dermatological recommendations sucha as use of skin moisturizers , sunscreen and topical steroids , according to toxicity severity .", "label": "", "metadata": {}, "score": "54.386772"}
{"text": "Byinvestigatorassessment , HRwas0.41(95 % CI,0.31to0.55;P ?SubgroupanalysesshowedthePFSbenefit forafatinibpersistedamongmostclinicallyrelevantsubgroupsexam- ined ( age , sex , race , Eastern Cooperative Oncology Group status ) , although many subgroups were underpowered for meaningful con- clusions ( Fig 2C ) .", "label": "", "metadata": {}, "score": "54.392815"}
{"text": "PMCID :PMC4306943 PMID : 25591040 .gemcitabine ; pazopanib ; phase I ; safety ; soft tissue sarcoma ; trabectedin .The objectives of this phase I study were to determine the maximum tolerated dose ( MTD ) , toxicity profile and pharmacokinetics of a 24-hour continuous intravenous infusion of trabectedin administered to children and adolescents with refractory or relapsed solid tumors .", "label": "", "metadata": {}, "score": "54.43278"}
{"text": "Trabectedin ( ecteinascidin-743 ) is a tetrahydroiso - quinoline alkaloid which has been evaluated in the treatment of metastatic soft tissue sarcoma .Aims : .", "label": "", "metadata": {}, "score": "54.53566"}
{"text": "Dose modifications , which were based on individual tolerability , re- ducedexcessiveafatiniblevelsandthusthevariabilityobservedinthe 40-mgdosegroupfrom85.0%(day1ofcycletwo)to66.5%(day1of cycle three ; Appendix Fig A2A , online only ) .", "label": "", "metadata": {}, "score": "54.583336"}
{"text": "Progression - Free Survival ( PFS ) : Independent Radiologist Review [ Time Frame : From the date of randomization until the date of disease progression or death , as assessed for approximately 3 years ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "54.599396"}
{"text": "One hundred sixty - nine patients ( 43.7 % ) in the panobinostat arm and 192 patients ( 50.4 % ) in the placebo arm continued to treatment phase 2 .", "label": "", "metadata": {}, "score": "54.608818"}
{"text": "Here , we report the response achieved in a patient with lung metastases from synovial sarcoma .A man with a large synovial sarcoma of the axilla underwent three cycles of neoadjuvant epirubicin+ifosfamide before complete excision , followed by three additional cycles of chemotherapy and radiotherapy .", "label": "", "metadata": {}, "score": "54.63421"}
{"text": "Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .No text entered .Patients received vemurafenib 960 mg ( four 240 mg tablets ) bid ( bis in die , twice daily ) orally until disease progression , unacceptable toxicity , withdrawal of consent , or another reason as determined by the investigator .", "label": "", "metadata": {}, "score": "54.67626"}
{"text": "We analyzed retrospectively the outcome of patients with localized high grade MPNST admitted to our institute from 1969 to 2008 .A review of the literature is also reported .", "label": "", "metadata": {}, "score": "54.689457"}
{"text": "Using the PubMed database , a systematic review of peer - reviewed literature published between January 2000 and September 2009 was undertaken to identify studies related to the treatment of patients with PSROC with PLD - Carbo or Gem - Carbo .", "label": "", "metadata": {}, "score": "54.69604"}
{"text": "Until now , there has been no standard of care after failure of or intolerance to doxorubicin and/or ifosfamide .An adjusted indirect comparison would be the most appropriate way to compare results of RCTs , but in this case since none of the RCTs had common arms to enable a formal indirect comparison , close attention should be paid to the findings of the individual trials .", "label": "", "metadata": {}, "score": "54.766197"}
{"text": "In the PALETTE study , there was a 3-month gain in PFS for pazopanib compared with BSC [ 12 ] .However , an imbalance in the use of PTACT between the two treatment arms may have affected the translation of the PFS benefit to OS .", "label": "", "metadata": {}, "score": "54.77931"}
{"text": "Overall , four of the six included RCTs reported data related to treatment discontinuations .In the Phase III PALETTE trial , pazopanib was associated with a higher proportion of patients discontinuing treatment due to AEs compared with placebo ( Table 4 ) [ 19 ] .", "label": "", "metadata": {}, "score": "54.896133"}
{"text": "No adverse event was associated with tetracycline .Neither rash nor pre - emptive tetracycline impacted on response rate , progression - free or overall survivals .", "label": "", "metadata": {}, "score": "54.919098"}
{"text": "Among 19 patients with breast cancer , four had evidence of a clinical benefit .Pharmacokinetic and pharmacodynamic studies did not show any significant interactions between the two drugs .", "label": "", "metadata": {}, "score": "54.94423"}
{"text": "215 - 223 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Blomqvist , R. Johansson , and M. Tarkkanen , \" Trabectedin in the treatment of metastatic soft - tissue sarcoma : cost - effectiveness and cost - utility are yet to be proved , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "55.023586"}
{"text": "Twenty - seven patients were included between April 1999 and September 2000 .Their median age was 54 years ( range : 36 - 67 ) and 63 % of them had two metastatic sites .", "label": "", "metadata": {}, "score": "55.164627"}
{"text": "Time to deterioration of pain was also longer with afatinib , butitwasnotstatisticallysignificant(HR,0.83;95%CI,0.62 to1.10;P ?Treatment - Related AEs Both treatments were well tolerated , and AEs were manageable with dose reductions and delays .", "label": "", "metadata": {}, "score": "55.194965"}
{"text": "Among men pretreated with taxane - based chemotherapy , PSA response was 13.6 % ( Cohort A ) and 15.4 % ( Cohort B2 ) .", "label": "", "metadata": {}, "score": "55.230904"}
{"text": "OSdidnotdiffer betweenafatinibandchemotherapyintheoverallstudypopulation(HR , 1.12;95%CI,0.73to1.73;P ? .60;25thpercentile,16.6v14.8months ) .Median OS has not yet been reached for any group .A high degree of postprogressioncrossovertoEGFRTKIsamongpatientsreceivingchem- otherapy ( 65 % ) and to chemotherapy among those receiving afatinib ( 62%)wasobserved .", "label": "", "metadata": {}, "score": "55.25537"}
{"text": "This file describes the details of prospective non - randomised studies with sample size more than 10 with respect to study design , sample size , median duration of follow - up , prior therapy , ECOG performance status , and STS sub - type .", "label": "", "metadata": {}, "score": "55.259903"}
{"text": "[ 10 ] .However , posttreatment anticancer therapy ( PTACT ) was received by 62 % in the placebo group compared with 45 % in the pazopanib group at the data cutoff date [ 12 ] , which may have diluted the survival benefit of pazopanib .", "label": "", "metadata": {}, "score": "55.302063"}
{"text": "Prolonged trabectedin treatment thus allows testing the importance of maintenance treatment .Interestingly , among the 56 patients who were not progressing after 6 cycles , the 40 who continued treatment had a significantly better PFS and more surprisingly OS , with a more than doubling of the median OS .", "label": "", "metadata": {}, "score": "55.312534"}
{"text": "The most common treatment- related adverse events were diarrhea , rash / acne , and stomatitis for afatinib and nausea , fatigue , and decreased appetite for chemotherapy .", "label": "", "metadata": {}, "score": "55.348297"}
{"text": "Five randomly assigned patients withdrewbeforereceivinganystudymedication .Treatment arms were balanced in terms of patient demographics andclinicalcharacteristics(Table1 ) .Asexpectedforapopulationselected byvirtueofEGFRmutations,72%ofpatientswereEastAsian,68%were never - smokers , and65%werewomen .", "label": "", "metadata": {}, "score": "55.46006"}
{"text": "One - month pain palliation was only observed in a minority of subjects and in none at 4 months .Based on our series , the PFS is dramatically short even when higher activity of ( 153)Sm - EDTMP is administered .", "label": "", "metadata": {}, "score": "55.4775"}
{"text": "Methods : We initiated within the German Interdisciplinary Sarcoma Group ( GISG ) a phase I dose escalating trial evaluating the combination of trabectedin and gemcitabine in patients with advanced and/or metastatic L - sarcomas ( GISG-02 ; ClinicalTrials.gov NCT01426633 ) .", "label": "", "metadata": {}, "score": "55.523598"}
{"text": "The CA-125 marker responses correlated with the radiological findings of complete response or partial response .The median PFS was 6.0 months ( 95 % CI , 4.2 - 7.9 ) and median survival was 17.8 months .", "label": "", "metadata": {}, "score": "55.664917"}
{"text": "This was the only study to report quality of life data .Based on the EORTC QLQ - C30 questionnaire , no clinically meaningful or statistically significant differences in global health status were observed between pazopanib and placebo patients remaining on treatment at the assessment time points [ 18 , 19 ] .", "label": "", "metadata": {}, "score": "55.69062"}
{"text": "This is the case of a 56 year old Caucasian man affected by a relapsed de - differentiated liposarcoma who , after the fourth cycle of second - line chemotherapy with trabectedin , complained of sudden weakness , difficulty walking and diffuse muscle pain necessitating complete bed rest .", "label": "", "metadata": {}, "score": "55.72946"}
{"text": "Facility costs for administering trabectedin and ifosfamide were based on a weighted average of the outpatient and day case 2010/2011 NHS reference costs for HRG SB14Z , \" delivery of complex chemotherapy ( including prolonged infusional treatment at first attendance ) \" [ 35 ] .", "label": "", "metadata": {}, "score": "55.747993"}
{"text": "Pao W , Miller VA , Politi KA , et al : Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain .", "label": "", "metadata": {}, "score": "55.756138"}
{"text": "The CBR was 29 % ( 95 % CI 13 % to 44 % ) .Noteworthy , tumor density reduction and [ ( 18)F]2-fluoro-2-deoxy - d - glucose - positron emission tomography responses were observed among SD patients .", "label": "", "metadata": {}, "score": "55.828903"}
{"text": "Two drugs , pegylated liposomal doxorubicin ( PLD ) and carboplatin were administered at three dose levels ( PLD : 10 , 20 , 50 mg and carboplatin 60 , 120 , 300 mg ) .", "label": "", "metadata": {}, "score": "56.001656"}
{"text": "Non - dose limiting toxicities included elevated serum transaminases , myelosuppression , nausea , emesis and fatigue .Plasma pharmacokinetic parameters were similar to historical data in adults .", "label": "", "metadata": {}, "score": "56.08012"}
{"text": "A : Progression - free survival in the whole cohort .C : Overall survival in the whole cohort .Response to treatment .Partial response ( PR ) , stable disease ( SD ) , and progressive disease ( PD ) were recorded as best response in 10 % , 39 % , 46 % of the patients respectively , with 5 % patients being non evaluable .", "label": "", "metadata": {}, "score": "56.121998"}
{"text": "Treatment Patientswererandomlyassignedinatwo - to - onefashiontooralafatinib 40 mg once per day or intravenous cisplatin 75 mg / m2and pemetrexed 500 mg / m2onceevery21daysuptoamaximumofsixcycles .Randomizationwas stratified by type of EGFR mutation ( L858R , exon 19 deletion , or other ) and race ( Asian or non - Asian ) .", "label": "", "metadata": {}, "score": "56.13128"}
{"text": "A total of 56 ( 31.1 % ) patients were in SD or PR after 6 cycles .In 16 , the treatment was stopped , whereas in 40 patients it was continued beyond 6 cycles for a median of 9 cycles ( range 7 - 19 ) .", "label": "", "metadata": {}, "score": "56.145035"}
{"text": "Scagliotti GV , Parikh P , von Pawel J , et al : Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced - stage non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "56.180786"}
{"text": "The survival and response rates of these patients were comparable to those reported in clinical trials .Interestingly , maintenance treatment after 6 cycles was associated with improved PFS and OS over treatment discontinuation after 6 cycles .", "label": "", "metadata": {}, "score": "56.19802"}
{"text": "Overall GR were 146 ( 49 % ) .Twenty - eight PR did not receive HDT .At a median follow - up of 64 months ( 21 - 116 months ) , 5-year overall and event - free survival ( EFS ) were 75 % and 69 % , respectively .", "label": "", "metadata": {}, "score": "56.23395"}
{"text": "Conclusions The recommended dose of trabectedin for phase II studies is 1.2 mg / m2 in Japanese patients with STS .Trabectedin may be especially effective against translocation - related sarcomas .", "label": "", "metadata": {}, "score": "56.24584"}
{"text": "The median follow - up was 62 months ( range 24 - 124 ) .One toxic death and one secondary leukemia were recorded .New treatment approaches are warranted for patients responding poorly to primary chemotherapy .", "label": "", "metadata": {}, "score": "56.30072"}
{"text": "PubMed .Zelek L , Yovine A , Brain E , et al .: A phase II study of Yondelis ( trabectedin , ET-743 ) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer .", "label": "", "metadata": {}, "score": "56.312973"}
{"text": "The objective of this study was to determine the sensitivity of a panel of primary USC cell lines to the small tyrosine kinase inhibitor neratinib , an ErbB1 and HER2 inhibitor , both in vitro and in vivo .", "label": "", "metadata": {}, "score": "56.31434"}
{"text": "Bibliographic searching of included trials and systematic reviews was also performed .Study selection and characteristics .The review included randomised controlled trials ( RCTs ) and non - randomised studies ( prospective and retrospective studies ) in patients with pre - treated advanced STS .", "label": "", "metadata": {}, "score": "56.384388"}
{"text": "Pharmacokinetic studies were conducted during cycle 1 . Results .At the 1.5 mg / m2 dose level , one patient had dose limiting anorexia and fatigue .", "label": "", "metadata": {}, "score": "56.441933"}
{"text": "After screening , a total of six RCTs ( reported in 13 publications and two Clinical Study Reports ) and 94 non - randomised studies ( reported in 105 publications ) met the inclusion criteria for the review .", "label": "", "metadata": {}, "score": "56.446953"}
{"text": "Deaths that occurred in patients without disease progression were considered to be a PFS event on the date of death .Patients who neither progressed nor died were censored on the date of the last evaluable tumor assessment prior to the data cutoff date .", "label": "", "metadata": {}, "score": "56.459766"}
{"text": "Trabectedin was the most frequently used third - line therapy , followed by investigational drugs [ 9 ] .Current UK treatment guidelines recommend treatment with trabectedin , gemcitabine , gemcitabine plus docetaxel , or ifosfamide for patients who fail initial chemotherapy with doxorubicin - based therapy [ 5 , 7 ] .", "label": "", "metadata": {}, "score": "56.489265"}
{"text": "Scagliotti G , Hanna N , Fossella F , et al : The differential efficacy of pemetrexed according to NSCLC histology : A review of two phase III studies .", "label": "", "metadata": {}, "score": "56.500732"}
{"text": "Cox proportional hazard models were used to compare PFS between arms , and Kaplan - Meier estimates were calculated .PFS analysis in patients with common EGFR mutations ( L858R and exon 19 deletions ) was prespecified .", "label": "", "metadata": {}, "score": "56.522915"}
{"text": "The investigation of afatinib in patients harbouring HER2/neu - amplified USC is warranted .Key information relevant to the recruitment process for the overall study , such as dates of the recruitment period and locations .", "label": "", "metadata": {}, "score": "56.572617"}
{"text": "The dose administered ranged from 30 to 60 Gy in 3 - 8 fractions .Acute and late toxicity were scored according to Common Terminology Criteria for Adverse Events version 4.0 .", "label": "", "metadata": {}, "score": "56.605347"}
{"text": "phase I ; proteasome inhibition ; bortezomib ; pegylated liposomal doxorubicin ; breast cancer .Canfosfamide is a novel glutathione analog activated by glutathione S - transferase P1 - 1 .", "label": "", "metadata": {}, "score": "56.711903"}
{"text": "9829 , pp .1879 - 1886 , 2012 .View at Publisher \u00b7 View at Google Scholar .T. E. Delea , P. Tappenden , O. Sofrygin et al . , \" Cost - effectiveness of lapatinib plus capecitabine in women with HER2 + metastatic breast cancer who have received prior therapy with trastuzumab , \" The European Journal of Health Economics , vol .", "label": "", "metadata": {}, "score": "56.911987"}
{"text": "Indirect Comparisons .Results for comparisons of pazopanib versus ifosfamide , trabectedin , and gemcitabine plus docetaxel are summarized in Table 6 .Pazopanib was estimated to gain 0.040 , 0.029 , and 0.001 QALYs versus ifosfamide , trabectedin , and gemcitabine plus docetaxel , respectively .", "label": "", "metadata": {}, "score": "57.069206"}
{"text": "Background .The long term outcome of advanced sarcoma patients treated with trabectedin outside of clinical trials and the utility of maintenance treatment has not been reported .", "label": "", "metadata": {}, "score": "57.07263"}
{"text": "N Engl J Med 361:947 - 957 , 2009 3 .Mitsudomi T , Morita S , Yatabe Y , et al : Gefitinib versuscisplatinplusdocetaxelinpatientswithnon - small- cell lung cancer harbouring mutations of the epidermal growth factor receptor ( WJTOG3405 ) : An open label , randomisedphase3trial .", "label": "", "metadata": {}, "score": "57.096798"}
{"text": "PFS and OS for the entire patient population were 32 % [ 95 % confidence interval ( CI ) 16 - 50 ] and 76 % ( 95 % CI 52 - 89 ) at 4 months , respectively .", "label": "", "metadata": {}, "score": "57.106773"}
{"text": "[PubMed ] .Le Cesne A , Antoine E , Spielmann M , Le CT , Brain E , Toussaint C , Janin N , Kayitalire L , Fontaine F , Genin J. High - dose ifosfamide : circumvention of resistance to standard - dose ifosfamide in advanced soft tissue sarcomas .", "label": "", "metadata": {}, "score": "57.169895"}
{"text": "Exploratorysubgroupanalysesfor commonmutationsareshowninAppendixFigureA1(onlineonly ) .Thenumbersofuncommonmutationsweretoosmall(26inafatinib arm ; 11 in chemotherapy arm ) for further analysis , although out- comesforthosereceivingafatinibwillbeanalyzedtogetherwiththose forpatientswithuncommonmutationsfromotherafatinibstudies . Significantlyhigherresponserateswereobservedwithafatinibcom-paredwithchemotherapyaccordingtobothindependent(56%and23 % , respectively ) and investigator ( 69 % and 44 % , respectively ) assessments ( bothP ?", "label": "", "metadata": {}, "score": "57.189445"}
{"text": "5 , pp .589 - 603 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. E. Delea , K. el Ouagari , J. Rotter , A. Wang , S. Kaura , and G. J. Morgan , \" Cost - effectiveness of zoledronic acid compared with clodronate in multiple myeloma , \" Current Oncology , vol .", "label": "", "metadata": {}, "score": "57.25451"}
{"text": "PMCID : PMC3003617 PMID : 20643863 . pegylated liposomal doxorubicin ; platinum - free interval ; relapsed ovarian cancer ; trabectedin .Intraductal administration of cytotoxic agents has been shown to inhibit the development of breast cancer in animal models .", "label": "", "metadata": {}, "score": "57.267845"}
{"text": "Flow cytometry was used to determine the effects of neratinib on cell viability , cell cycle distribution and signaling in vitro .Mice harboring HER2/neu amplified xenografts were treated with neratinib to assess the efficacy of the drug in vivo .", "label": "", "metadata": {}, "score": "57.31186"}
{"text": "Decoster LV , Vande Broek I , Anckaert E , De Mey J , Denys H , Canon J , De Clerck D , Neyns B , De Greve J. Activity of sunitinib in advanced soft tissue sarcoma and its correlation with potential predictive biomarkers .", "label": "", "metadata": {}, "score": "57.372498"}
{"text": "Yang JC , Shih JY , Su WC , et al : Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations ( LUX - Lung 2 ) : A phase 2 trial .", "label": "", "metadata": {}, "score": "57.40397"}
{"text": "HRs for PFS for each comparator versus pazopanib were estimated using data from published studies of the comparators of interest that were identified based on a systematic review of the literature ( Table 2 ) .", "label": "", "metadata": {}, "score": "57.4167"}
{"text": "Al - Saleh K , Quinton C , Ellis PM : Role of pem- etrexed in advanced non - small - cell lung cancer : Meta - analysis of randomized controlled trials , with histology subgroup analysis .", "label": "", "metadata": {}, "score": "57.549496"}
{"text": "PubMed View Article .Van Glabbeke M , van Oosterom AT , Oosterhuis JW , et al .: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma : an analysis of 2,185 patients treated with anthracycline - containing first - line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study .", "label": "", "metadata": {}, "score": "57.56682"}
{"text": "2014;32:5s ( suppl ; abstr 8510 ) .Dimopoulos M , Siegel DS , Lonial S , et al .Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma ( VANTAGE 088 ) : a multicentre , randomised , double - blind study .", "label": "", "metadata": {}, "score": "57.59999"}
{"text": "Data abstraction .Relevant data from all included studies were extracted using a pre - defined extraction grid .Data extraction was conducted in parallel by two independent reviewers with any differences resolved by a third independent reviewer .", "label": "", "metadata": {}, "score": "57.630157"}
{"text": "Sequist LV , Waltman BA , Dias - Santagata D , et al : Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors .", "label": "", "metadata": {}, "score": "57.755905"}
{"text": "Grade 3 toxicities in later cycles included hand - foot syndrome , thrombocytopenia , anemia , neutropenia , nausea , diarrhea , and abdominal pain .", "label": "", "metadata": {}, "score": "57.81308"}
{"text": "Overall , AEs were not consistently reported across the RCTs included in the review .Across the Phase II trials , haematological AEs were commonly experienced with treatments including dacarbazine , gemcitabine plus dacarbazine , and trabectedin .", "label": "", "metadata": {}, "score": "57.84203"}
{"text": "RESULTS : Thirty - five patients were enrolled .PFS at 4 months was 46 % ( 95 % CI 28 % to 63 % ) .", "label": "", "metadata": {}, "score": "57.90008"}
{"text": "PATIENTS AND METHODS Study Design and Patients LUX - Lung3wasaglobal , randomized , open - labelphaseIIIstudycom- paring first - line afatinib with cisplatin plus pemetrexed chemotherapy in pa- tientswithadvancedlungadenocarcinomaandprovenEGFRmutations .", "label": "", "metadata": {}, "score": "57.907135"}
{"text": "Results of the PALETTE trial showed pazopanib improved progression - free survival ( PFS ) versus placebo ( median 4.6 versus 1.6 months , resp .", "label": "", "metadata": {}, "score": "57.95039"}
{"text": "5 , pp . e371-e387 , 2013 .View at Publisher \u00b7 View at Google Scholar .S. Sharma , S. Takyar , S. C. Manson , S. Powell , and N. Penel , \" Efficacy and safety of pharmacological interventions in second- or later - line treatment of patients with advanced soft tissue sarcoma : a systematic review , \" BMC Cancer , vol .", "label": "", "metadata": {}, "score": "58.13452"}
{"text": "The protocol is registered on clinicaltrials.gov ( NCT01880515 ) .Results We included 90 patients , no differences were found in clinical and dermatological baseline characteristics .", "label": "", "metadata": {}, "score": "58.15888"}
{"text": "Minuzzo M , Marchini S , Broggini M , Faircloth G , D'Incalci M , Mantovani R : Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743 .", "label": "", "metadata": {}, "score": "58.279503"}
{"text": "The traditional cytotoxic drugs commonly induce haematological toxicities whereas grade 3/4 toxicities seen with pazopanib included fatigue , elevated liver enzymes , and hypertension ( Table 3 ) .", "label": "", "metadata": {}, "score": "58.37816"}
{"text": "J Clin Oncol .2011 ; 29 : Abstract no .LBA10002 .Duffaud F , Bui BN , Penel N , Cioffi A , Isambert N , Blay JY , Cupissol D , Jimenez M , Rey A , Pautier P. A FNCLCC French Sarcoma Group -- GETO multicenter randomized phase II study of gemcitabine ( G ) versus gemcitabine and docetaxel ( G+D ) in patients with metastatic or relapsed leiomyosarcoma ( LMS ) Abstract American Society of Oncology ( ASCO )", "label": "", "metadata": {}, "score": "58.410885"}
{"text": "The optimal management of patients with partially platinum - sensitive relapse [ 6 - 12 months platinum - free interval ( PFI ) ] is unclear .", "label": "", "metadata": {}, "score": "58.428314"}
{"text": "PubMed ] .Italiano A , Mathoulin - Pelissier S , Cesne AL , Terrier P , Bonvalot S , Collin F , Michels JJ , Blay JY , Coindre JM , Bui B. Trends in survival for patients with metastatic soft - tissue sarcoma .", "label": "", "metadata": {}, "score": "58.571743"}
{"text": "[PubMed ] .Look KY , Sandler A , Blessing JA , Lucci JA III , Rose PG .Phase II trial of gemcitabine as second - line chemotherapy of uterine leiomyosarcoma : A Gynecologic Oncology Group ( GOG )", "label": "", "metadata": {}, "score": "58.70211"}
{"text": "A positive trend for adjuvant radiation , but not for chemotherapy was observed according to univariate analysis only for disease - free survival and overall survival .", "label": "", "metadata": {}, "score": "58.711926"}
{"text": "Options used in clinical practice include ifosfamide , trabectedin , gemcitabine in combination with docetaxel , and dacarbazine - based regimens [ 9 ] .With the advent of new targeted therapies for treatment of advanced STS , it is important to understand the current evidence base in this setting .", "label": "", "metadata": {}, "score": "58.71772"}
{"text": "Toqualifyforenrollment , apatient'stumorhadtoharboranactivating mutationinEGFRwhentestedatoneofthreecentrallaboratoriesemploying astandardizedallele - specificquantitativereal - timepolymerasechainreaction kit ( Therascreen EGFR 29 ; Qiagen , Manchester , United Kingdom ) .In addi- tion , eligible patients had treatment - naive advanced lung adenocarcinoma ; goodperformancestatus , definedas0or1ontheEasternCooperativeOncol- ogy Group scale12 ; adequate end - organ function ; and measurable disease using RECIST version 1.1.13A list of the EGFR mutations detectable by Therascreenandthefulleligibilitycriteriaareprovidedintheprotocol .", "label": "", "metadata": {}, "score": "58.751053"}
{"text": "The primary analysis focused on direct comparisons of pazopanib versus BSC .In this analysis , data on PFS and OS for placebo patients from PALETTE were used without any adjustment of OS for the differential receipt of PTACT in the two groups .", "label": "", "metadata": {}, "score": "58.755524"}
{"text": "Table 2 : Studies used in indirect treatment comparison of progression - free survival .Therefore , a mapping algorithm was developed using data for the EQ-5D and QLQ - C30 at baseline and four weeks to predict EQ-5D utility values at 8 and 12 weeks given the responses to the EORTC QLQ - C30 at those later assessments [ 21 ] .", "label": "", "metadata": {}, "score": "58.8069"}
{"text": "Population and patient characteristics .Between 2003 and 2008 , 87 centres have included 328 patients in the ATU program .The present study was performed on 181 patients from 11 centres having treated at least 5 patients who agreed to participate .", "label": "", "metadata": {}, "score": "58.83397"}
{"text": "[PubMed ] .Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy .J Clin Oncol .", "label": "", "metadata": {}, "score": "58.89102"}
{"text": "Previous treatments included bortezomib ( 43 % ) , thalidomide ( 51 % ) , and lenalidomide ( 20 % ) .Twenty - five percent of patients had received both bortezomib and immunomodulatory agents .", "label": "", "metadata": {}, "score": "58.956474"}
{"text": "All statistical tests were 2-sided , and a p - value below 0.050 was considered statistically significant .This study was approved by the local institutional review board at each participating institution .", "label": "", "metadata": {}, "score": "59.04978"}
{"text": "To determine the maximum tolerated dose ( MTD ) of trabectedin plus gemcitabine administered on a weekly schedule in patients with advanced solid tumors .Methods .", "label": "", "metadata": {}, "score": "59.098534"}
{"text": "The cost - effectiveness of pazopanib was expressed as the incremental costs per QALY gained .Estimates of PFS / OS , adverse events , and utilities for pazopanib and placebo were from the PALETTE trial .", "label": "", "metadata": {}, "score": "59.10338"}
{"text": "Objective response according to RECIST ( v.1.0 ) was a secondary end point .Three of 23 assessable patients had pCR [ 13 % ; 95 % confidence interval ( CI ) , 3 % to 34%].", "label": "", "metadata": {}, "score": "59.171772"}
{"text": "The safety of trabectedin / PLD in this subset mimicked that of the overall population .Similar proportions of patients received subsequent therapy in each arm ( 76 % versus 77 % ) , although patients in the trabectedin / PLD arm had a slightly lower proportion of further platinum ( 49 % versus 55 % ) .", "label": "", "metadata": {}, "score": "59.250347"}
{"text": "From first treatment through September 27 , 2010 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "59.477592"}
{"text": "Toxicity resulted in treatment discontinuation in 36 % and 20 % of patients in the panobinostat and placebo arms , respectively .The all - cause death rate was 8 % and 5 % , respectively .", "label": "", "metadata": {}, "score": "59.538284"}
{"text": "Bergman B , Aaronson NK , Ahmedzai S , et al : The EORTC QLQ - LC13 : A modular supplement to the EORTC Core Quality of Life Questionnaire ( QLQ- C30 ) for use in lung cancer clinical trials - EORTC Study Group on Quality of Life .", "label": "", "metadata": {}, "score": "59.54543"}
{"text": "Data from the PALETTE trial were combined with data from a vignettes study to estimate utility values for the PPS state [ 13 , 23 ] .", "label": "", "metadata": {}, "score": "59.574818"}
{"text": "[PubMed ] .J Immunother .[PubMed ] .Lopez M , Carpano S , Dilauro L , Chiatti L , Vici P , Cavaliere F , Gentile P , Citro G. Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft - tissue sarcomas .", "label": "", "metadata": {}, "score": "59.637028"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Intent - to - treat population : All enrolled patients who received at least one , or a partial dose of vemurafenib .", "label": "", "metadata": {}, "score": "59.727364"}
{"text": "Only centres that had included more than 5 patients actually contributed to this retrospective study .These centres treated 252 patients in total , among which 181 patient files ( 71 % ) were collected and updated as of March 20 th , 2012 .", "label": "", "metadata": {}, "score": "59.748802"}
{"text": "These results suggest pazopanib is dominant ( i.e. , lower costs and greater QALYs ) compared with each comparator .In probabilistic sensitivity analyses , there was an estimated 100 % probability that pazopanib is cost - effective versus ifosfamide or trabectedin and 98 % probability versus gemcitabine plus docetaxel .", "label": "", "metadata": {}, "score": "59.778786"}
{"text": "Afatinib could be considered a standardoptionforsuchpatients .Certain relationships marked with a \" U \" are those for which no compensation was received ; those relationships marked with a \" C \" were compensated .", "label": "", "metadata": {}, "score": "59.86312"}
{"text": "Covariates were sarcoma subtype , age and pretreatment .On average , trabectedin was administered for 2nd relapse / progression ( range 1st to 12th line ) .", "label": "", "metadata": {}, "score": "59.89438"}
{"text": "Response rate was defined for each arm as the proportion of patients with best overall RECISTresponseofCRorPR , dividedbythetotalnumberofpatientsrandomly assignedtothatarm;logisticregressionmodelswereusedtocomparearms .Safety analyses included all patients receiving at least one dose of trial medication . Descriptivestatisticswereusedforallothersecondaryandexplor- atory analyses .", "label": "", "metadata": {}, "score": "59.974953"}
{"text": "Due to the paucity of RCT evidence in this anthracyline pre - treated setting , this review included RCTs and non - randomised studies ( prospective and retrospective ) to allow for a detailed description of the evidence supporting these interventions being used for the management of patients with pre - treated advanced STS .", "label": "", "metadata": {}, "score": "59.987736"}
{"text": "PubMed View Article .Cassier PA , Dufresne A , Fayette J , Alberti L , Ranchere D , Ray - Coquard I , Blay JY : Emerging drugs for the treatment of soft tissue sarcomas .", "label": "", "metadata": {}, "score": "60.076027"}
{"text": "Lancet Oncol 13:247- 255 , 2012 33 .Sandler A , Gray R , Perry MC , et al : Paclitaxel- carboplatin alone or with bevacizumab for non - small- cell lung cancer .", "label": "", "metadata": {}, "score": "60.07673"}
{"text": "Table 4 suggests that discontinuations due to AEs may be more frequent with pazopanib , possibly because oncologists are less familiar with managing the side effects associated with this agent unlike the classical cytotoxic haemotological toxicities , which have been known for years .", "label": "", "metadata": {}, "score": "60.08084"}
{"text": "PubMed View Article .Le Cesne A , Blay JY , Judson I , et al .: Phase II study of ET-743 in advanced soft tissue sarcomas : a European Organisation for the Research and Treatment of Cancer ( EORTC ) soft tissue and bone sarcoma group trial .", "label": "", "metadata": {}, "score": "60.08572"}
{"text": "[PubMed ] .Spath - Schwalbe E , Genvresse I , Koschuth A , Dietzmann A , Grunewald R , Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas .", "label": "", "metadata": {}, "score": "60.125854"}
{"text": "Model Estimation .A summary of model inputs can be found in Table 1 .PFS , OS , and PPS were estimated for pazopanib and placebo by fitting parametric survival functions to patient - level data from PALETTE using accelerated failure time regression ( Figure 1 ) [ 19 ] .", "label": "", "metadata": {}, "score": "60.13906"}
{"text": "The median number of cycles was 3 ( range 1 - 19 ) .Thirty patients ( 17 % ) had to be hospitalized for treatment- related side effects .", "label": "", "metadata": {}, "score": "60.144245"}
{"text": "PMCID : PMC2598415 PMID :18497430 .ET-743 ; ovarian cancer ; pegylated liposomal doxorubicin ( PLD ) ; sarcomas ; trabectedin .To determine the dose of trabectedin plus doxorubicin with granulocyte colony stimulating factor ( G - CSF ) support associated with manageable neutropenia and acceptable dose - limiting toxicities ( DLTs ) in patients with recurrent or persistent soft tissue sarcoma ( STS ) .", "label": "", "metadata": {}, "score": "60.149086"}
{"text": "Thus , we explored sorafenib activity in patients with relapsed and unresectable osteosarcoma .The primary end point was progression - free survival ( PFS ) at 4 months .", "label": "", "metadata": {}, "score": "60.169426"}
{"text": "[PubMed ] .Mouridsen HT , Bastholt L , Somers R , Santoro A , Bramwell V , Mulder JH , van Oosterom AT , Buesa J , Pinedo HM , Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas .", "label": "", "metadata": {}, "score": "60.18065"}
{"text": "The model was designed to permit two alternative approaches to estimate the proportion of patients in each health state over time .With the \" partitioned - survival analysis \" approach , survival distributions for PFS and OS were entered into the model , and the proportion of patients in the PPS state was calculated as the difference between OS and PFS .", "label": "", "metadata": {}, "score": "60.223106"}
{"text": "Doxorubicin , alone or combined with ifosfamide , is the standard of care for first - line treatment of STS [ 5 , 7 , 8 ] .", "label": "", "metadata": {}, "score": "60.25505"}
{"text": "Progression - free survival , assessed by modified EBMT criteria , was the primary endpoint of the study .Secondary endpoints included overall survival ( OS ) , overall response rate ( ORR ) , near complete / complete response ( nCR / CR ) rate , duration of response ( DOR ) , and safety .", "label": "", "metadata": {}, "score": "60.27298"}
{"text": "The PK data revealed no obvious drug interactions .Biweekly administration of PLD , PCX and GEM is a well - tolerated chemotherapy regimen , which merits further evaluation in various types of solid tumours .", "label": "", "metadata": {}, "score": "60.279385"}
{"text": "p. AbstractNo . : 10060 .J Clin Oncol .[PubMed ] .Chawla S , Casali PG , von Mehren M , Le Cesne A , Blay JY , Lebedinsky C , Alfaro V , Elsayed Y , Michiels B , Demetri GD .", "label": "", "metadata": {}, "score": "60.286644"}
{"text": "[PubMed ] .Penel N , Van GM , Marreaud S , Ouali M , Blay JY , Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma : analysis of publications from the last 10 years .", "label": "", "metadata": {}, "score": "60.287216"}
{"text": "Gynecol Oncol .[PubMed ] .Babovic N , Jelic S , Milanovic N , Matkovic S. Pilot study of daily ifosfamide 1 g / m2 until grade III granulocytopenia as second - line chemotherapy for anthracycline - pretreated advanced soft tissue sarcoma .", "label": "", "metadata": {}, "score": "60.409523"}
{"text": "A lack of recent improvement in survival in TYA with bone tumours may be linked to a lack of specialist care , poor concordance with therapy in some situations and TYA - specific pharmacology .", "label": "", "metadata": {}, "score": "60.4982"}
{"text": "PubMed View Article .Sessa C , De Braud F , Perotti A , et al .: Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails .", "label": "", "metadata": {}, "score": "60.63667"}
{"text": "Patients and methods : A detailed analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity was therefore conducted .", "label": "", "metadata": {}, "score": "60.720367"}
{"text": "W. T. van der Graaf , J. Y. Blay , S. P. Chawla , et al . , \" Pazopanib for metastatic soft - tissue sarcoma ( PALETTE ) : a randomized , double - blind , placebo - controlled phase 3 trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "60.727627"}
{"text": "PubMed .Judson I , Radford JA , Harris M , et al .: Randomised phase II trial of pegylated liposomal doxorubicin ( DOXIL / CAELYX ) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma : a study by the EORTC Soft Tissue and Bone Sarcoma Group .", "label": "", "metadata": {}, "score": "60.733578"}
{"text": "PubMed .Izbicka E , Lawrence R , Raymond E , et al .:In vitro antitumor activity of the novel marine agent , ecteinascidin-743 ( ET-743 , NSC-648766 ) against human tumors explanted from patients .", "label": "", "metadata": {}, "score": "60.78669"}
{"text": "The PFS rate , 1-year OS rate , and ORR also favoured the q3w 24-hour dosing schedule over the qw 3-hour dosing schedule .", "label": "", "metadata": {}, "score": "60.9245"}
{"text": "[PubMed ] .Ferraresi V , Ciccarese M , Cercato MC , Nuzzo C , Zeuli M , Di FF , Giannarelli D , Cognetti F. Gemcitabine at fixed dose - rate in patients with advanced soft tissue sarcomas : A mono - institutional phase II study .", "label": "", "metadata": {}, "score": "60.993557"}
{"text": "The secondary outcome measures evaluated across these studies included OS , response , DOR , TTR , dose reductions / interruptions , safety , and withdrawals .", "label": "", "metadata": {}, "score": "61.00652"}
{"text": "Buesa JM , Mouridsen HT , van Oosterom AT , Verweij J , Wagener T , Steward W , Poveda A , Vestlev PM , Thomas D , Sylvester R. High - dose DTIC in advanced soft - tissue sarcomas in the adult .", "label": "", "metadata": {}, "score": "61.072536"}
{"text": "The mean duration of PTACT was assumed to be 4 months , which was an average of the mean PFS in the placebo and pazopanib arms in PALETTE ( 2.5 and 6 months , resp . )", "label": "", "metadata": {}, "score": "61.084076"}
{"text": "Hanna N , Shepherd FA , Fossella FV , et al : Randomized phase III trial of pemetrexed versus docetaxel in patients with non - small - cell lung cancer previously treated with chemotherapy .", "label": "", "metadata": {}, "score": "61.174118"}
{"text": "Gynecol Oncol .[ PMC free article ] [ PubMed ] .Van Glabbeke M , Verweij J , Judson I , Nielsen OS .Progression - free rate as the principal end - point for phase II trials in soft - tissue sarcomas .", "label": "", "metadata": {}, "score": "61.18978"}
{"text": "Inclusion criteria of the ATU were those of the EORTC trial .The only difference was that no restrictions were imposed on the previous number of lines .", "label": "", "metadata": {}, "score": "61.34278"}
{"text": "A total of 22/62 are alive ; 26 patients had surgery alone , 18 received radiation therapy , 12 received radiation therapy and chemotherapy , and 6 received only adjuvant chemotherapy .", "label": "", "metadata": {}, "score": "61.36503"}
{"text": "Declarations .Competing interests .JYB , AI , BNB , ALC , IRC , NP , FD received research support and honoraria from Pharmamar .", "label": "", "metadata": {}, "score": "61.369377"}
{"text": "Li D , Ambrogio L , Shimamura T , et al : BIBW2992 , an irreversible EGFR / HER2 inhibitor highly effective in preclinical lung cancer models .", "label": "", "metadata": {}, "score": "61.383614"}
{"text": "The primary end point was PFS by independent review .Secondary end points included tumor response , overall survival , adverse events , and patient - reported outcomes ( PROs ) .", "label": "", "metadata": {}, "score": "61.455406"}
{"text": "Tetracyclines are usually used to treat it ; nonetheless , there is no trial that evaluates their prophylactic efficacy on afatinib induced - skin toxicities ( AIST ) .", "label": "", "metadata": {}, "score": "61.460403"}
{"text": "This review aims at summarizing the available evidence about the clinical role of trabectedin in the management of patients with epithelial ovarian cancer .Novel perspectives coming from a better understanding of trabectedin mechanisms of action and definition of patients subgroups likely susceptible to benefit of trabectedin treatment are also presented .", "label": "", "metadata": {}, "score": "61.462677"}
{"text": "No concurrent antitumor therapy was allowed .Mesothelioma , chondrosarcoma , neuroblastoma , osteosarcoma , Ewing 's sarcoma , embryonal rhabdomyosarcoma , and dermatofibrosarcoma were excluded .", "label": "", "metadata": {}, "score": "61.612106"}
{"text": "[PubMed ] .Palumbo R , Palmeri S , Gatti C , Villani G , Cesca A , Toma S. Combination chemotherapy using vincristine , adriamycin , cyclophosphamide ( VAC ) alternating with ifosfamide and etoposide ( IE ) for advanced soft tissue sarcomas : A phase II study .", "label": "", "metadata": {}, "score": "61.636894"}
{"text": "Of the most common AEs associated with afatinib , only diarrhea ( 1.3 % ) and paronychia ( 0.9 % ) resulted in treatment discontinuation .", "label": "", "metadata": {}, "score": "61.65606"}
{"text": "J Clin Oncol .[PubMed ] .Budd GT , Metch B , Weiss SA , Weick JK , Fabian C , Stephens RL , Balcerzak SP .", "label": "", "metadata": {}, "score": "61.758717"}
{"text": "904 - 912 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. Mayrb\u00e4url , L. M. Wintner , J. M. Giesinger et al . , \" Chemotherapy line - associated differences in quality of life in patients with advanced cancer , \" Supportive Care in Cancer , vol .", "label": "", "metadata": {}, "score": "61.785217"}
{"text": "over single - agent PLD in 672 patients with relapsed ovarian cancer , particularly in the partially platinum - sensitive subgroup [ platinum - free interval ( PFI ) of 6 - 12 months].", "label": "", "metadata": {}, "score": "61.880974"}
{"text": "Cancer Chemother Pharmacol .[PubMed ] .Ann Oncol .2008 ; 19 : viii270 .Vaughn CB , McKelvey E , Balcerzak SP , Loh K , Stephens R , Baker L. High - dose methotrexate with leucovorin rescue plus vincristine in advanced sarcoma : A Southwest Oncology Group study .", "label": "", "metadata": {}, "score": "61.986557"}
{"text": "Diarrhea , rash , and dryness or irritation of the skin , mucosa , and nails were the most common treatment - related AEs with afatinib , whereas decreased appetite , fatigue , nausea / vomiting , and myelosuppression were most com- mon with chemotherapy ( Table 2 ) .", "label": "", "metadata": {}, "score": "62.157146"}
{"text": "The only activity data reported in this study was SD in all four patients receiving sorafenib or placebo at 12 weeks [ 28 ] .Activity data were also not reported in the conference abstract for the TAXOGEM study by Pautier and colleagues [ 27 ] .", "label": "", "metadata": {}, "score": "62.157215"}
{"text": "Oken MM , Creech RH , Tormey DC , et al : Toxicity and response criteria of the Eastern Coop- erative Oncology Group .Am J Clin Oncol 5:649 - 655 , 1982 13 .", "label": "", "metadata": {}, "score": "62.207794"}
{"text": "Twenty - seven patients with primary ES of the mobile spine were treated from 1979 to 2008 by the same multidisciplinary team .All the patients presented with pain .", "label": "", "metadata": {}, "score": "62.224518"}
{"text": "Overall survival according to the best response to trabectedin .Overall survival of patients whose best response was : partial response ( light brown ) , stable disease ( purple ) , progressive disease ( green ) , or non evaluable ( blue ) .", "label": "", "metadata": {}, "score": "62.284355"}
{"text": "Eur J Cancer .[PubMed ] .Thigpen JT , Blessing JA , Wilbanks GD .Cisplatin as second - line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus .", "label": "", "metadata": {}, "score": "62.315834"}
{"text": "RESULTS Patients Thisstudywasperformedat133centersin25countriesinAsia , Europe , North America , South America , and Australia .Between Au- gust2009andFebruary2011,1,269patientswerescreenedtoidentify and randomly assign 345 eligible patients with EGFR mutations ( Fig 1 ) .", "label": "", "metadata": {}, "score": "62.37985"}
{"text": "Cancer Chemother Pharmacol .1993 ; 31 : S213-S216 .[PubMed ] .Saeter G , Talle K , Solheim OP .Treatment of advanced , high - grade soft - tissue sarcoma with ifosfamide and continuous - infusion etoposide .", "label": "", "metadata": {}, "score": "62.417694"}
{"text": "[PubMed ] .Ray - Coquard I , Le CA , Whelan JS , Schoffski P , Bui BN , Verweij J , Marreaud S , Van GM , Hogendoorn P , Blay JY .", "label": "", "metadata": {}, "score": "62.488102"}
{"text": "The primary end point was prostate - specific antigen ( PSA ) response ; secondary end points included safety , tolerability and time to progression ( TTP ) .", "label": "", "metadata": {}, "score": "62.525482"}
{"text": "PubMed View Article .Pommier Y , Kohlhagen G , Bailly C , Waring M , Mazumder A , Kohn KW : DNA sequence- and structure - selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743 , a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata .", "label": "", "metadata": {}, "score": "62.572273"}
{"text": "[PubMed ] .Gravis G , Mousseau M , Douillard JY , Dorval T , Fabbro M , Escudier B , Mignot L , Viens P. Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients .", "label": "", "metadata": {}, "score": "62.59795"}
{"text": "10 , pp .2399 - 2405 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. A. Elmqvist , M. S. Jordh\u00f8y , K. Bjordal , S. Kaasa , and M. Jannert , \" Health - related quality of life during the last three months of life in patients with advanced cancer , \" Supportive Care in Cancer , vol .", "label": "", "metadata": {}, "score": "62.63461"}
{"text": "E J Cancer Clin Oncol .[PubMed ] .Crawley CR , Judson IR , Verrill M , Hill C , Raynaud FI .A phase I / II study of a 72-h continuous infusion of etoposide in advanced soft tissue sarcoma .", "label": "", "metadata": {}, "score": "62.63779"}
{"text": "The samples size was calculated to be 330 patients and the estimated timeofprimaryanalysistobeapproximately2yearsafterstudyinitiation .No interim analyses to compare treatment arms were planned .All efficacy analyses wereperformedinanintent - to - treatmannerandincludedallrandomlyassigned patients .", "label": "", "metadata": {}, "score": "62.72659"}
{"text": "Methods Patients who had STS refractory to , or who could not tolerate , anthracycline - based chemotherapy were enrolled .The starting dose of trabectedin was 0.9 mg / m2 , given as a 24-h continuous infusion every 21 days .", "label": "", "metadata": {}, "score": "62.735447"}
{"text": "2009 ; 151 : W65-W94 .[PubMed ] .Downs SH , Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non - randomised studies of health care interventions .", "label": "", "metadata": {}, "score": "62.7399"}
{"text": "PMCID : PMC3003616 PMID : 20643862 . pegylated liposomal doxorubicin ; platinum - free interval ; relapsed ovarian cancer ; trabectedin .Background : Evaluation of the potential efficacy and safety of combination therapies for advanced soft tissue sarcomas ( STS ) has increased substantially after approval of trabectedin and pazopanib .", "label": "", "metadata": {}, "score": "62.918335"}
{"text": "These therapies were the most relevant chemotherapy comparators in the UK based on treatment patterns reported in the SABINE study and consultation with clinical experts .", "label": "", "metadata": {}, "score": "62.961845"}
{"text": "However , these observations strengthen the rationale of the ongoing study randomizing treatment maintenance vs interruption after 6 cycles which is currently ongoing within the French Sarcoma Group ( NCT01303094 ) .", "label": "", "metadata": {}, "score": "62.96744"}
{"text": "All these patients died 2 to 29 months later without significant difference in the two groups .In the period 1983 to 1990 all patients were treated with chemotherapy ( REN-1/2 ) and RT .", "label": "", "metadata": {}, "score": "62.979126"}
{"text": "16 , no . 7 , p. A419 , 2013 .View at Publisher \u00b7 View at Google Scholar .J. M. Giesinger , L. M. Wintner , A. S. Oberguggenberger et al . , \" Quality of life trajectory in patients with advanced cancer during the last year of life , \" Journal of Palliative Medicine , vol .", "label": "", "metadata": {}, "score": "63.000275"}
{"text": "Current guidelines including the European Society for Medical Oncology and the National Comprehensive Cancer Network treatment guidelines recommend anthracycline - based chemotherapy - primarily with doxorubicin , either as monotherapy or in combination with ifosfamide , as the first - line treatment for most advanced STS subtypes [ 7 , 8 ] .", "label": "", "metadata": {}, "score": "63.004665"}
{"text": "Background .Current guidelines recommend anthracycline - based chemotherapy primarily with doxorubicin either as monotherapy or in combination with ifosfamide as the first - line treatment for most advanced STS subtypes .", "label": "", "metadata": {}, "score": "63.120552"}
{"text": "Duration of response was calculated from the date of first documentation of response ( not the confirmation ) to the date of disease progression or death due to progressive disease .", "label": "", "metadata": {}, "score": "63.163307"}
{"text": "The efficacy / toxicity ratio of therapies which have limited Phase II evidence should be further evaluated in phase III trials based on formal statistical assumptions , and should include parameters such as median overall survival and quality of life .", "label": "", "metadata": {}, "score": "63.26757"}
{"text": "The search of the literature databases yielded 9542 separate references .Following the screening of abstracts against the inclusion / exclusion criteria , 545 full - text reports were obtained for detailed evaluation .", "label": "", "metadata": {}, "score": "63.429295"}
{"text": "infusion every 3 weeks is a therapeutic option in the neoadjuvant setting of ML .[ Show abstract ] [ Hide abstract ] ABSTRACT : Purpose : After standard multimodal therapy , the prognosis of relapsed and unresectable high - grade osteosarcoma is dismal and unchanged over the last decades .", "label": "", "metadata": {}, "score": "63.5269"}
{"text": "[PubMed ] .Skubitz KM , Hamdan H , Thompson RC Jr. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas .Cancer .", "label": "", "metadata": {}, "score": "63.53668"}
{"text": "Clin Cancer Res 15:5317 - 5322 , 2009 22 .Zhou Q , Zhang XC , Chen ZH , et al : Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "63.54139"}
{"text": "In the phase III PALETTE trial , pazopanib improved progression - free survival ( PFS ) compared with placebo in patients with advanced / metastatic soft tissue sarcomas ( mSTS ) who had received prior chemotherapy .", "label": "", "metadata": {}, "score": "63.554405"}
{"text": "J Clin Oncol 16:139 - 144 , 1998 17a .Yang JC - H , Hirsh V , Schuler M , et al : Symp- tom control and quality of life in LUX - Lung 3 : A phase III study of afatinib or cisplatin / pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations .", "label": "", "metadata": {}, "score": "63.602165"}
{"text": "Clin Cancer Res 17:1160 - 1168 , 2011 28 .Gazdar AF : Activating and resistance muta- tions of EGFR in non - small - cell lung cancer : Role in clinical response to EGFR tyrosine kinase inhibitors .", "label": "", "metadata": {}, "score": "63.60969"}
{"text": "The details of the grade 3 and/or 4 AEs observed across these studies are provided in an additional file ( see Additional file 7 ) .", "label": "", "metadata": {}, "score": "63.719105"}
{"text": "Patients randomly assigned to chemotherapy received folic acid , vitamin B12 , and dexamethasone , as per package rec- ommendations for pemetrexed .No maintenance chemotherapy was per- mitted .", "label": "", "metadata": {}, "score": "63.751225"}
{"text": "The patient was discharged on day 14 when a blood transfusion and parenteral hydration gradually lowered general toxicity .Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings .", "label": "", "metadata": {}, "score": "63.777138"}
{"text": "Table 5 : Base - case results for direct comparison of cost - effectiveness of pazopanib versus placebo .Results for the deterministic sensitivity analysis are presented in Figure 2 .", "label": "", "metadata": {}, "score": "63.81928"}
{"text": "Targeted radiation therapy has been pursued as a valid alternative .The primary end point of this study was progression - free survival ( PFS ) at 4 months .", "label": "", "metadata": {}, "score": "63.846672"}
{"text": "PubMed ] .Le Cesne A , Blay JY , Judson I , van OA , Verweij J , Radford J , Lorigan P , Rodenhuis S , Ray - Coquard I , Bonvalot S , Collin F , Jimeno J , Di PE , Van GM , Nielsen OS .", "label": "", "metadata": {}, "score": "63.892113"}
{"text": "Histological decrement in the cellular and vascular tumor component and maturation of tumor cells to lipoblasts were observed in both myoxid and myoxid / round cell variants .", "label": "", "metadata": {}, "score": "63.905586"}
{"text": "In addition to the literature database search , abstracts from conference proceedings including American Society of Clinical Oncology , European Society for Medical Oncology , European Conference for Clinical Oncology , Connective Tissue Oncology Society and Musculoskeletal Tumour Society were hand searched from 2007 to March 2012 .", "label": "", "metadata": {}, "score": "63.947407"}
{"text": "The dose of 1.5 mg / m2 ( approved for soft tissue sarcoma ) given as 24-h infusion q3wk was not tolerable in these patients .", "label": "", "metadata": {}, "score": "63.95314"}
{"text": "1697 - 1706 , 2013 .View at Publisher \u00b7 View at Google Scholar .P. Swinburn , A. Lloyd , P. Nathan , T. K. Choueiri , D. Cella , and M. P. Neary , \" Elicitation of health state utilities in metastatic renal cell carcinoma , \" Current Medical Research and Opinion , vol .", "label": "", "metadata": {}, "score": "63.99594"}
{"text": "Zhou C , Wu YL , Chen G , et al : Erlotinib versus chemotherapy as first - line treatment for patients with advanced EGFR mutation - positive non - small- cell lung cancer ( OPTIMAL , CTONG-0802 ) : A multi- centre , open - label , randomised , phase 3 study .", "label": "", "metadata": {}, "score": "64.024185"}
{"text": "In view of limited RCT evidence , data from non - randomised studies was evaluated .Antitumour activity of gemcitabine monotherapy [ 75 ] and gemcitabine plus docetaxel [ 88 , 89 ] in patients with uterine leiomyosarcoma was also indicated by the non - RCT evidence .", "label": "", "metadata": {}, "score": "64.04956"}
{"text": "However , possibly due to the high usage rate of salvage treatment after progression , this improvement in PFS did not translate into an OS advantage ( Table 2 ) .", "label": "", "metadata": {}, "score": "64.06992"}
{"text": "The dose intensity reported in Gem trials was lower ( 75 % of the planned dose ) than the dose intensity reported in PLD trials ( 93.7 % of the planned dose ) , suggesting better tolerability for the PLD - Carbo regimen .", "label": "", "metadata": {}, "score": "64.155754"}
{"text": "PubMed ] .Eur J Cancer Clin Oncol .[PubMed ] .Kostler WJ , Brodowicz T , Attems Y , Hejna M , Tomek S , Amann G , Fiebiger WC , Wiltschke CH , Krainer M , Zielinski CC .", "label": "", "metadata": {}, "score": "64.23337"}
{"text": "Duration of Response : Independent Radiologist Review [ Time Frame : From the date of first documentation of response to the date of disease progression or death due to progressive disease , as assessed for approximately 3 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.32225"}
{"text": "Maemondo M , Inoue A , Kobayashi K , et al : Gefitinib or chemotherapy for non - small - cell lung cancer with mutated EGFR .", "label": "", "metadata": {}, "score": "64.385994"}
{"text": "The mean follow - up time was 65 months ( median 28 months ; ranging 2 to 218 months ) .Neurological function , local recurrence , distant relapse , and treatment - related complications were evaluated .", "label": "", "metadata": {}, "score": "64.40075"}
{"text": "RCTs involve randomisation which minimises the selection bias and confounding , and are therefore the most rigorous way of determining comparative efficacy .Despite the systematic approach employed in this review , it was limited by the identification of only a small number of RCTs and the lack of comparability in terms of sample size , study design , and patient populations across both the RCTs and non - randomised studies .", "label": "", "metadata": {}, "score": "64.496826"}
{"text": "Maintenance therapy maybe a strategy worth further exploring in patients with advanced STS .Conclusion .Trabectedin is confirmed as an active and safe agent for the treatment of advanced STS patients who have failed to standard therapies .", "label": "", "metadata": {}, "score": "64.51816"}
{"text": "Rosell R , Carcereny E , Gervais R , et al : Erlo- tinib versus standard chemotherapy as first - line treatment for European patients with advanced EGFR mutation - positive non - small - cell lung cancer ( EURTAC ) : A multicentre , open - label , randomised phase 3 trial .", "label": "", "metadata": {}, "score": "64.58685"}
{"text": "J Clin Oncol .[PubMed ] .Sleijfer S , Ray - Coquard I , Papai Z , Le CA , Scurr M , Schoffski P , Collin F , Pandite L , Marreaud S , De BA , Van GM , Verweij J , Blay JY .", "label": "", "metadata": {}, "score": "64.656555"}
{"text": "The median PFS times were 10.6 months and 8.9 months in the PLD - Carbo and the Gem - Carbo populations , respectively .The median OS was longer for the PLD - Carbo regimen ( 27.1 months ) than for the Gem - Carbo regimen ( 19.7 months ) .", "label": "", "metadata": {}, "score": "64.718056"}
{"text": "Probabilistic sensitivity analysis and acceptability curves for the comparison of pazopanib and placebo are presented in Figures 3(a ) and 3(b ) , respectively .A high concentration of simulations was present in the north - eastern quadrant of the cost - effectiveness plane .", "label": "", "metadata": {}, "score": "64.771416"}
{"text": "Estimates of the incidence of AEs for pazopanib and placebo were from the PALETTE trial .Estimates of the incidence of AEs for chemotherapies were based on reported values in the literature .", "label": "", "metadata": {}, "score": "64.77349"}
{"text": "191 - 198 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. S. Hwang , V. T. Chang , D. L. Fairclough , J. Cogswell , and B. Kasimis , \" Longitudinal quality of life in advanced cancer patients : pilot study results from a VA Medical Cancer Center , \" Journal of Pain and Symptom Management , vol .", "label": "", "metadata": {}, "score": "64.79376"}
{"text": "PFS was superior in patients with myxoid liposarcomas , retroperitoneal sarcomas and grade 1 tumors ( Table 1 ) .OS was superior in patients with myxoid liposarcomas , retroperitoneal sarcomas and grade 1 tumors ( Table 1 ) .", "label": "", "metadata": {}, "score": "64.99605"}
{"text": "Ovarian cancer ; Platinum ; Pegylated liposomal doxorubicin ; Gemcitabine ; Carboplatin .Among the pharmaceutical options available for treatment of ovarian cancer , attention has been increasingly focused on trabectedin ( ET-743 ) , a drug which displays a unique mechanism of action and has been shown to be active in several human malignancies .", "label": "", "metadata": {}, "score": "65.03418"}
{"text": "General considerations ; pp . 1 - 19 .Spira AI , Ettinger DS .The use of chemotherapy in soft - tissue sarcomas .Oncologist .", "label": "", "metadata": {}, "score": "65.05561"}
{"text": "Inaddition , patientstreatedwithafatinibhadstatisticallysignifi- ca nt and clinically meaningful improvements in response rate and lung cancer symptoms .Afatinib treatment was associated with man- ageableAEs , andhence , discontinuationbecauseofdrug - relatedAEs waslow .", "label": "", "metadata": {}, "score": "65.06914"}
{"text": "Bertuzzi A , Stroppa E , Secondino S , Zucali P , Quagliuolo V , Pedrazzoli P , Comandone A , Basso U , Soto Parra H , Santoro A. Efficacy and toxicity of sorafenib in patients with advanced soft tissue sarcoma failing anthracycline - based chemotherapy .", "label": "", "metadata": {}, "score": "65.14665"}
{"text": "Thus , it was difficult to draw any conclusions regarding the comparative tolerability of the evaluated interventions [ 74 , 82 , 83 ] .Discussion .", "label": "", "metadata": {}, "score": "65.17608"}
{"text": "( C ) Forest plot of subgroups of patients showing PFS by independent review .HR , hazard ratio ; ECOG , Eastern Cooperative Oncology Group .", "label": "", "metadata": {}, "score": "65.17996"}
{"text": "Mediandurationofresponsewasindependently assessed as 11.1 and 5.5 months for afatinib and chemotherapy , respec- tively , whereas median duration of disease control was 13.6 and 8.1 months , respectively .", "label": "", "metadata": {}, "score": "65.2029"}
{"text": "We describe the results qualitatively with detailed results presented in supporting tables .The results are presented separately for RCTs and non - randomised studies .", "label": "", "metadata": {}, "score": "65.23912"}
{"text": "The PALETTE trial has formally demonstrated the benefit of treating patients with anti - angiogenic agent over placebo in terms of PFS in a Phase III setting ( Table 2 ) [ 18 , 19 ] .", "label": "", "metadata": {}, "score": "65.34892"}
{"text": "[PubMed ] .Demetri GD .ET-743 : The US experience in sarcomas of soft tissues .Anti -Cancer Drugs .2002 ; 13 : S7-S9 .", "label": "", "metadata": {}, "score": "65.42032"}
{"text": "[ PMC free article ] [ PubMed ] .Dombernowsky P , Buesa J , Pinedo HM , Santoro A , Mouridsen H , Somers R , Bramwell V , Onsrud M , Rouesse J , Thomas D. VP-16 in advanced soft tissue sarcoma : A phase II study of the EORTC soft tissue and bone sarcoma group .", "label": "", "metadata": {}, "score": "65.429474"}
{"text": "Figure 2 : Tornado diagram showing result of deterministic sensitivity analysis for the direct comparison of cost - effectiveness of pazopanib versus placebo .Parameters were varied by 0.5 or 1.5 and shown on either side of the graph .", "label": "", "metadata": {}, "score": "65.54152"}
{"text": "Overall survival of partial responders and patients with SD were similar in the first years , but only partial responders were long - term survivors beyond 5 years ( 44 % ) .", "label": "", "metadata": {}, "score": "65.64369"}
{"text": "EGFR testing should be tightly woven into lung cancer diagnostic workup algorithmsworldwide .Key strengths of this study were central EGFR mutation testing and central review of radiographs .", "label": "", "metadata": {}, "score": "65.67616"}
{"text": "2010 ; 21 ( Suppl 5):v198-v203 .[PubMed ] .Leahy M , Garcia DM X , Reichardt P , Judson I , Staddon A , Verweij J , Baffoe - Bonnie A , Jonsson L , Musayev A , Justo N , Burke T , Blay JY .", "label": "", "metadata": {}, "score": "65.71256"}
{"text": "Analysis : Did the analysis include an intention - to - treat analysis ?If so , was this appropriate and were appropriate methods used to account for missing data ?", "label": "", "metadata": {}, "score": "65.73117"}
{"text": "Abstract at European Cancer Organisation ( ECCO )Ann Meet Eur J Cancer .2007 ; 5 : Abstract No . :7517 .Pacey S , Ratain MJ , Flaherty KT , Kaye SB , Cupit L , Rowinsky EK , Xia C , O'Dwyer PJ , Judson IR .", "label": "", "metadata": {}, "score": "65.81072"}
{"text": "Combination arm - Trabectedin + DOXIL : DOXIL 30 mg / m2 intravenous ( IV ) infusion over 90 minutes + trabectedin 1.1 mg / m2 IV infusion over 3 hours every 3 weeks .", "label": "", "metadata": {}, "score": "65.81996"}
{"text": "10 : 2647 - 2658 .[ Show abstract ] [ Hide abstract ] ABSTRACT : Background : The purpose of this study was to evaluate local control and toxicity in a group of patients treated with stereotactic body radiotherapy ( SBRT ) for lung metastases ( LM ) from bone and soft tissue sarcomas .", "label": "", "metadata": {}, "score": "65.933334"}
{"text": "References .Richardson PG , Hungria VTM , Yoon SS , et al .Panorama 1 : A randomized , double - blind , phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma .", "label": "", "metadata": {}, "score": "66.01518"}
{"text": "Panobinostat increases acetylation of proteins involved in multiple oncogenic pathways , inducing cancer cell death .In preclinical research in multiple myeloma , panobinostat was synergistic with bortezomib and dexamethasone .", "label": "", "metadata": {}, "score": "66.026634"}
{"text": "Central radiology interpretation is important to reduce bias in the interpretationofPFS.Inourstudy , diseaseprogressionwasrecorded by investigators more often than by independent reviewers , particu- larlyamongpatientsrandomlyassignedtochemotherapy(chemother- apy arm : 83 progression events by investigators v 69 by independent review;afatinibarm:155byinvestigatorsv152bycentralreview ) .", "label": "", "metadata": {}, "score": "66.145584"}
{"text": "Outpatient treatment is well tolerated also in elderly and heavily pretreated patients .Port - associated complications were observed at an unusually high rate .This suggests a drug - specific local toxicity that merits further investigation .", "label": "", "metadata": {}, "score": "66.20418"}
{"text": "The file describes the quality assessment of RCTs undertaken on the following parameters : Randomisation : was randomisation carried out appropriately ?Allocation concealment : Was the concealment of treatment allocation adequate ?", "label": "", "metadata": {}, "score": "66.28417"}
{"text": "PubMed ] .Patel SR , Linke KA , Burgess MA , Papadopoulos NE , Plager C , Jenkins J , Benjamin R. Phase II study of paclitaxel in patients with soft tissue sarcomas .", "label": "", "metadata": {}, "score": "66.30029"}
{"text": "Conclusions : Neratinib may be a potential treatment option for patients harboring HER2/neu amplified USC .Clinical trials for this subset of endometrial cancer patients are warranted . \"", "label": "", "metadata": {}, "score": "66.37528"}
{"text": "Authors ' disclosures of potential conflicts of interest and author contributions are found at the end of this article .Clinical trial information : NCT00949650 .", "label": "", "metadata": {}, "score": "66.414444"}
{"text": "6 , pp . e392-e403 , 2012 .View at Google Scholar .T. E. Delea , J. Amdahl , A. Chit , and M. M. Amonkar , \" Cost - effectiveness of lapatinib plus letrozole in HER2-positive , hormone receptor - positive metastatic breast cancer in Canada , \" Current Oncology , vol .", "label": "", "metadata": {}, "score": "66.48948"}
{"text": "Conclusion Afatinib is associated with prolongation of PFS when compared with standard doublet chemo- therapy in patients with advanced lung adenocarcinoma and EGFR mutations .J Clin Oncol 31:3327 - 3334 .", "label": "", "metadata": {}, "score": "66.603645"}
{"text": "2008 ; 26 : Abstract No . : 10511 .Lancet .[PubMed ] .Leahy M , Ray - Coquard I , Verweij J , Le CA , Duffaud F , Hogendoorn PC , Fowst C , de BC , di Paola ED , Van GM , Judson I , Blay JY .", "label": "", "metadata": {}, "score": "66.64157"}
{"text": "Sharma SV , Bell DW , Settleman J , et al : Epidermal growth factor receptor mutations in lung cancer .Nat Rev Cancer 7:169 - 181 , 2007 2 .", "label": "", "metadata": {}, "score": "66.657074"}
{"text": "[PubMed ] .Docetaxel and gemcitabine combination in 133 advanced soft - tissue sarcomas : a retrospective analysis .Int J Cancer .[PubMed ] .", "label": "", "metadata": {}, "score": "66.78726"}
{"text": "Plasma samples were collected during cycles 1 and 2 for pharmacokinetic analyses .Results .The most common drug - related toxicity was hepatic .Dose reductions were required for trabectedin in four ( 27 % ) patients and gemcitabine in six ( 40 % ) patients .", "label": "", "metadata": {}, "score": "66.79205"}
{"text": "DISCUSSION Toourknowledge , LUX - Lung3isthelargestprospective , randomized trialreportedtodateinpatientswithadvancedstageEGFRmutation- positive NSCLC and the first study to compare first - line EGFR- targetedTKItherapywiththebest - in - classchemotherapyregimenof cisplatinpluspemetrexed .", "label": "", "metadata": {}, "score": "66.80147"}
{"text": "The association between surgical margins and overall survival ( OS ) was studied in a univariate and multivariate fashion .ResultsTwo hundred and fifty - two patients completed the whole treatment and were operated conservatively .", "label": "", "metadata": {}, "score": "66.80386"}
{"text": "Between 2003 and 2008 , patients with advanced sarcoma failing doxorubicin could be treated within a compassionate use program ( ATU , Temporary Use Authorization ) of trabectedin in France using the standard 3-weekly regimen .", "label": "", "metadata": {}, "score": "66.88486"}
{"text": "It would have been of interest to compare this series to that of patients treated in non - expert centres but this could not be obtained .", "label": "", "metadata": {}, "score": "66.97861"}
{"text": "Clin Cancer Res .[PubMed ] .Keohan ML , Grever MR , Balcerzak SP , Antman K. A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma .", "label": "", "metadata": {}, "score": "66.994705"}
{"text": "The figure describes the flow of studies through the review , according to PRISMA guidelines .The search of the literature databases yielded 9542 separate references .", "label": "", "metadata": {}, "score": "67.00251"}
{"text": "Zewail - Foote M , Hurley LH : Ecteinascidin 743 : a minor groove alkylator that bends DNA toward the major groove .J Med Chem 1999 , 42 : 2493 - 2497 .", "label": "", "metadata": {}, "score": "67.065926"}
{"text": "The treatment for STS is largely dictated by the tumour grade , size , location of metastatic sites , and the histological subtype [ 4 , 6 , 7 ] .", "label": "", "metadata": {}, "score": "67.10241"}
{"text": "PMC4302088 PMID : 25556617 .Trabectedin ; ovarian cancer ; DNA repair ; platinum - sensitive ovarian cancer .Background Trabectedin is a novel anticancer agent used to treat soft tissue sarcoma ( STS ) .", "label": "", "metadata": {}, "score": "67.14159"}
{"text": "225 - 235 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. L. Shingler , P. Swinburn , A. Lloyd , et al . , \" Elicitation of health state utilities in soft tissue sarcoma , \" Quality of Life Research , vol .", "label": "", "metadata": {}, "score": "67.1592"}
{"text": "Direct Comparison .In the base - case analyses ( Table 5 ) , pazopanib was estimated to increase QALYs by 0.128 and costs by \u00a3 7,976 compared with placebo .", "label": "", "metadata": {}, "score": "67.190704"}
{"text": "Conclusion .From a UK healthcare system perspective , taking into account the threshold of \u00a3 30,000/QALY , pazopanib is not cost - effective compared with BSC ( base - case ) ; however , pazopanib might be cost - effective compared with trabectedin , ifosfamide , or gemcitabine when used in combination with docetaxel .", "label": "", "metadata": {}, "score": "67.25374"}
{"text": "This study was a cost - effectiveness evaluation of pazopanib in the treatment of patients with aSTS who have received prior chemotherapy from the perspective of the UK healthcare system .", "label": "", "metadata": {}, "score": "67.28788"}
{"text": "Median simulated area under the curve ( AUC ) of a 21 day trabectedin profile of participants ( of this study ) administering trabectedin and doxil , calculated using the trapezoidal rule method .", "label": "", "metadata": {}, "score": "67.34839"}
{"text": "Side effects , including neutropenia , elevation of liver transaminases / liver function tests , and nausea / vomiting , were usually mild and manageable .", "label": "", "metadata": {}, "score": "67.39156"}
{"text": "Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian cancer .A randomized phase 3 study was conducted based on this supportive phase 2 study .", "label": "", "metadata": {}, "score": "67.513855"}
{"text": "Median Maximum Plasma Concentration ( Cmax ) of Trabectedin .Median simulated maximum plasma concentration ( Cmax ) at 3 hour of a 21 day trabectedin profile of participants ( of this study ) administering trabectedin and doxil .", "label": "", "metadata": {}, "score": "67.58365"}
{"text": "Detailedanalysesoftheseoutcomeshavebeen reportedelsewhere.17a AEs were categorized and graded using NCI - CTCAE version 3.0.18 An independent data safety monitoring board conducted ongoing assess- ments of efficacy and safety data .", "label": "", "metadata": {}, "score": "67.72622"}
{"text": "[PubMed ] .Tursz T. High - dose ifosfamide in the treatment of advanced soft tissue sarcomas .Semin Oncol .[PubMed ] .", "label": "", "metadata": {}, "score": "67.76965"}
{"text": "For OS , the two favorable prognostic factors in multivariate analysis were histological subtype of myxoid liposarcomas and retroperitoneal locations for primary disease ( Table 2 ) .", "label": "", "metadata": {}, "score": "67.80911"}
{"text": "The standard of care in the treatment of advanced and metastatic disease over the last 30 years has been doxorubicin and ifosfamide , either alone or in combination .", "label": "", "metadata": {}, "score": "67.85602"}
{"text": "The SArcoma treatment and Burden of Illness in North America and Europe ( SABINE ) study .Ann Oncol .[PubMed ] .Liberati A , Altman DG , Tetzlaff J , Mulrow C , Gotzsche PC , Ioannidis JP , Clarke M , Devereaux PJ , Kleijnen J , Moher D. The PRISMA statement for reporting systematic reviews and meta - analyses of studies that evaluate health care interventions : explanation and elaboration .", "label": "", "metadata": {}, "score": "67.88705"}
{"text": "Because data on OS is more likely to be impacted by differences in patient populations and trial design than data on PFS , it was believed that the comparisons would be more reliable if based on PFS alone rather than PFS and OS .", "label": "", "metadata": {}, "score": "67.9303"}
{"text": "W64 .[PubMed ] .Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma : a Spanish Group for Research on Sarcomas study .", "label": "", "metadata": {}, "score": "67.992615"}
{"text": "Rhabdomyolysis is an uncommon side effect of trabectedin which is used for the second line therapy of metastatic sarcoma after anthracycline and ifosfamide failure .This side effect may be due to pharmacokinetic interactions caused by shared mechanisms of metabolism involving the cytochrome P450 ( CYP ) system in the liver .", "label": "", "metadata": {}, "score": "68.23563"}
{"text": "Eur J Can- cer 45:228 - 247 , 2009 14 .Aaronson NK , Ahmedzai S , Bergman B , et al : The European Organisation for Research and Treat- ment of Cancer QLQ - C30 : A quality - of - life instru- ment for use in international clinical trials in oncology .", "label": "", "metadata": {}, "score": "68.284744"}
{"text": "Oncologist .[PubMed ] .Hartmann JT , Oechsle K , Huober J , Jakob A , Azemar M , Horger M , Kanz L , Bokemeyer C. An open label , non - comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma .", "label": "", "metadata": {}, "score": "68.292274"}
{"text": "Maheswaran S , Sequist LV , Nagrath S , et al : Detection of mutations in EGFR in circulating lung- cancer cells .N Engl J Med 359:366 - 377 , 2008 27 .", "label": "", "metadata": {}, "score": "68.30571"}
{"text": "Soft Tissue and Bone Sarcoma Group trial .J Clin Oncol .[PubMed ] .Yovine A , Riofrio M , Blay JY , Brain E , Alexandre J , Kahatt C , Taamma A , Jimeno J , Martin C , Salhi Y , Cvitkovic E , Misset JL .", "label": "", "metadata": {}, "score": "68.387726"}
{"text": "The frequency and severity of AEs were clearly greater at 1.5 mg / m2 than at the lower doses .Pharmacokinetic analysis showed that the area under the concentration - time curve at a dose of 1.2 mg / m2 was adequate to produce antitumor activity .", "label": "", "metadata": {}, "score": "68.626854"}
{"text": "Trial flow / flow of included studies .The flow of studies through the review , according to PRISMA guidelines [ 17 ] , is shown in Figure 1 .", "label": "", "metadata": {}, "score": "68.80262"}
{"text": "The comparability amongst this evidence was examined in light of recent Phase III trial evidence for pazopanib , a new oral selective tyrosine kinase inhibitor for the treatment of advanced STS .", "label": "", "metadata": {}, "score": "69.09682"}
{"text": "National Cancer Institute : Cancer Therapy Evalua- tionProgram : CommonTerminologyCriteriaforAdverse Events , version 3.0 .htm 19 .Thatcher N , Chang A , Parikh P , et al : Gefitinib plus best supportive care in previously treated pa- tients with refractory advanced non - small - cell lung cancer : Resultsfroma controlled , multicentre study ( Iressa Survival Evalu- ation in Lung Cancer ) .", "label": "", "metadata": {}, "score": "69.179344"}
{"text": "Kobayashi S , Boggon TJ , Dayaram T , et al : EGFR mutation and resistance of non - small - cell lung cancer to gefitinib .", "label": "", "metadata": {}, "score": "69.1796"}
{"text": "The objective of this retrospective study was to assess the outcome of STS patients treated in the French ATU compassionate use program and to compare it with that of published clinical trials .", "label": "", "metadata": {}, "score": "69.18887"}
{"text": "Transition probabilities were then derived from these inputs and combined to calculate the survival distribution for OS .Expected lifetime outcomes and costs were evaluated over a 10-year timeframe , approximating a lifetime projection for patients with aSTS ( i.e. , virtually all patients were projected to be dead after 10 years ) .", "label": "", "metadata": {}, "score": "69.19679"}
{"text": "The 5-year cumulative incidence ( CI ) of local recurrence ( LR ) in patients with positive and negative microscopic margins was 0.17 ( standard error , SE , 0.08 ) and 0.03 ( SE , 0.01 ) , respectively .", "label": "", "metadata": {}, "score": "69.214874"}
{"text": "CONCLUSION Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations .Full - text .", "label": "", "metadata": {}, "score": "69.22215"}
{"text": "There is a dearth of information regarding the cost - effectiveness of other systemic agents to treat aSTS in the UK .Soini and colleagues [ 40 ] evaluated the cost - effectiveness of trabectedin versus end - stage treatment in Finland and reported ICERs ranging from \u20ac", "label": "", "metadata": {}, "score": "69.2966"}
{"text": "When there were multiple studies evaluating a single intervention , variability was often observed in the efficacy and safety results , primarily attributed to differences in patient characteristics and assessment criteria used to evaluate efficacy measures .", "label": "", "metadata": {}, "score": "69.571335"}
{"text": "N. B. Jones , H. Iwenofu , T. Scharschmidt , and W. Kraybill , \" Prognostic factors and staging for soft tissue sarcomas : an update , \" Surgical Oncology Clinics of North America , vol .", "label": "", "metadata": {}, "score": "69.660965"}
{"text": "Shepherd FA , Rodrigues Pereira J , Ciuleanu T , et al : Erlotinib in previously treated non - small - cell lung cancer .N Engl J Med 353:123 - 132 , 2005 21 .", "label": "", "metadata": {}, "score": "69.72423"}
{"text": "Treatment Delivery and Efficacy Afatinibwasadministeredforamedianof11.0months(16cycles ) .Meanoverallcompliancewithafatinibassessedperpatientwas98 % .Dose reductiontolessthan40mgperdaywasrequiredfor120patients(52 % ) , Sequist et al 3328 \u00a9 2013 by American Society of Clinical Oncology Downloaded from jco.ascopubs.org on November 5 , 2015 .", "label": "", "metadata": {}, "score": "69.76042"}
{"text": "Am J Clin Oncol : Cancer Clin Trials .[PubMed ] .Bramwell VHC , Mouridsen HT , Santoro A , Blackledge G , Somers R , Verweij J , Dombernowsky P , Onsrud M , Thomas D , Sylvester R , van Oosterom A. Suppl 2 .", "label": "", "metadata": {}, "score": "69.76323"}
{"text": "1914 - 1926 , 2001 .View at Google Scholar .P. G. Casali , L. Jost , S. Sleijfer , J. Verweij , and J.-Y. Blay , \" Soft tissue sarcomas : ESMO clinical recommendations for diagnosis , treatment and follow - up , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "69.88082"}
{"text": "Effectiveness measures were calculated on a discounted and undiscounted basis ; costs were calculated on a discounted basis only .A 3.5 % annual discount rate was employed beginning at the end of the first year of the model [ 17 ] .", "label": "", "metadata": {}, "score": "69.882965"}
{"text": "Deterministic and probabilistic sensitivity analyses were undertaken to explore the effect of changing assumptions concerning key model parameter values on model results and cost - effectiveness acceptability curves generated [ 37 , 38 ] .", "label": "", "metadata": {}, "score": "69.936005"}
{"text": "Fivepatientserro- neouslybeganafatinibat50mgperday , and16(7%)exercisedtheoption toincreasefrom40to50mgperdayafterthefirstcycle .Mediannumber ofchemotherapycycleswassix;83patients(75%)received?fourcycles , and61(55%)receivedallsixcycles .Eighteenpatients(16%)hadachem- otherapydosereductionforAEs , andtreatmentadministrationwasde- layedby ?6daysin41patients(40 % ) .At the time of data cutoff for the primary analysis , median follow - uptimewas16.4months , and221progressionordeathevents , as assessed by independent review , had occurred .", "label": "", "metadata": {}, "score": "70.07892"}
{"text": "Centres .From 2003 to 2008 , 87 centres in France enrolled included at least one patient in the ATU ( \" Autorisation Temporaire d'Utilisation \" ) program , a compassionate use program for STS patients matching the inclusion criteria ( see below ) .", "label": "", "metadata": {}, "score": "70.12369"}
{"text": "Forest plot for subgroups of patients among those with common mutations , showing progression - free survival by ( A ) independent and ( B ) investigator review ( exploratory analyses ) .", "label": "", "metadata": {}, "score": "70.16249"}
{"text": "vii92-vii99 , 2012 .View at Publisher \u00b7 View at Google Scholar .M. Leahy , X. G. del Muro , P. Reichardt , et al . , \" Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma .", "label": "", "metadata": {}, "score": "70.35727"}
{"text": "Comparative studies were included if the intervention of interest was compared with placebo , best supportive care , or any of the included interventions .All studies retrieved by searches were screened according to above defined eligibility criteria .", "label": "", "metadata": {}, "score": "70.37492"}
{"text": "The objective of this paper is to assess the sensitivity of USC cell lines with and without HER2/neu gene amplification to afatinib , an irreversible ErbB tyrosine kinase inhibitor , and to test the efficacy of afatinib in the treatment of HER2-amplified USC xenografts .", "label": "", "metadata": {}, "score": "70.42431"}
{"text": "9 , no . 7 , pp .623 - 630 , 2000 .View at Google Scholar .M. D. Rawlins and A. J. Culyer , \" National institute for clinical excellence and its value judgments , \" British Medical Journal , vol .", "label": "", "metadata": {}, "score": "70.4393"}
{"text": "Median DOR , time to response , and time to progression , were 13.1 versus 10.9 months , 1.5 versus 2 months , and 12.7 versus 8.5 months , respectively .", "label": "", "metadata": {}, "score": "70.4883"}
{"text": "Drug : Trabectedin .Trabectedin will be administered over 3 hours every 3 weeks .Other Name : Yondelis .Drug : DOXIL .DOXIL will be administered over 90 minutes every 4 weeks when administered alone ( monotherapy ) and every 3 weeks when administered with trabectedin .", "label": "", "metadata": {}, "score": "70.565384"}
{"text": "[PubMed ] .J Clin Oncol .[PubMed ] .Demetri GD , Chawla SP , von MM , Ritch P , Baker LH , Blay JY , Hande KR , Keohan ML , Samuels BL , Schuetze S , Lebedinsky C , Elsayed YA , Izquierdo MA , Gomez J , Park YC , Le CA .", "label": "", "metadata": {}, "score": "70.60072"}
{"text": "This review demonstrates that non - randomised trials provide limited information ( Table 6 ) .Randomised studies are preferred when designing new trials .The safety profiles of chemotherapy agents versus pazopanib are clearly different , so additional data including compliance , quality of life and cost are needed to fully understand the extent of the differences between chemotherapy and targeted agents .", "label": "", "metadata": {}, "score": "70.65017"}
{"text": "Yondelis \u00ae ( trabectedin , ET-743 ) is a novel marine - derived anticancer compound found in the ascidian Ecteinascidia turbinata .It is currently under phase II / III development in breast cancer , hormone refractory prostate cancer , sarcomas and ovarian cancer .", "label": "", "metadata": {}, "score": "70.7543"}
{"text": "The list of retrospective studies and studies with a sample size less than 10 is also provided as an additional file ( see Additional file 6 ) .", "label": "", "metadata": {}, "score": "70.77905"}
{"text": "Assessments Tumorassessmentswereperformedbycomputedtomographyormag- neticresonanceimagingevery6weeksforthefirst48weeksandthenevery12 weeks thereafter until disease progression or start of new anticancer therapy .Scanswerereviewedbyanindependentcentralimaginggroupincorporating both radiologist and oncologist reviewers blinded to treatment assignments .", "label": "", "metadata": {}, "score": "70.80189"}
{"text": "Progression - free and overall survival according to maintenance after 6 cycles .No maintenance- treatment interruption after 6 cycles ( blue ) ; maintenance- treatment beyond 6 cycles ( green ) .", "label": "", "metadata": {}, "score": "70.94266"}
{"text": "Drug utilization was adjusted for dosage adjustment , early discontinuation , and interruptions .It was assumed that pazopanib would be provided to the UK National Health Service ( NHS ) at a 12.5 % discount to the list price consistent with a published patient access scheme ( PAS ) agreement between the NHS and GlaxoSmithKline [ 29 ] .", "label": "", "metadata": {}, "score": "71.03496"}
{"text": "To determine the maximum tolerated doses ( MTDs ) and dose - limiting toxicities ( DLTs ) of pegylated liposomal doxorubicin ( PLD ) , paclitaxel ( PCX ) and gemcitabine ( GEM ) combination administered biweekly in patients with advanced solid tumours .", "label": "", "metadata": {}, "score": "71.054504"}
{"text": "OS was based on intent - to - treat analyses .Survival distributions for pazopanib and placebo were estimated independently .Exponential , Weibull , and log - logistic models were considered .", "label": "", "metadata": {}, "score": "71.169075"}
{"text": "Centre Ren\u00e9 Gauducheau .Centre GF Leclerc .CHU Besan\u00e7on .Pharmamar .Centre Oscar Lambret .References .Casali PG , Blay JY , ESMO / CONTICANET / EUROBONET Consensus Panel of Experts : Gastrointestinal stromal tumours : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow - up .", "label": "", "metadata": {}, "score": "71.367714"}
{"text": "Invest New Drugs .[PubMed ] .Eur J Cancer .[PubMed ] .Hohenberge .A randomized , double - blind , phase III trial of pazopanib versus placebo in patients ( pts ) with soft - tissue sarcoma ( STS ) whose disease has progressed during or following prior chemotherapy An EORTC STBSG Global Network Study ( EORTC 62072 ) .", "label": "", "metadata": {}, "score": "71.4371"}
{"text": "The use of local adjuvant treatment , as phenol or liquid nitrogen , is suggested to decrease the risk of recurrence .In selected cases resection and reconstruction with a prosthesis are recommended to decrease the risk of recurrence .", "label": "", "metadata": {}, "score": "71.593025"}
{"text": "[PubMed ] .Cancer Treat Rep. 1984 ; 68 : 683 - 684 .[PubMed ] .Palumbo R , Raffo P , Capello C , Castagneto B , Gatti C , Toma S. Paclitaxel ( taxol ) in pretreated , relapsed and/or metastatic adult soft tissue sarcomas ( STS ) Oncol Rep. 1997 ; 4 : 127 - 130 .", "label": "", "metadata": {}, "score": "71.63999"}
{"text": "Figure 3 : ( a ) Probabilistic sensitivity analyses for comparison of cost - effectiveness of pazopanib versus placebo .( b ) Acceptability curve for comparison of cost - effectiveness of pazopanib versus placebo .", "label": "", "metadata": {}, "score": "71.8589"}
{"text": "Utility values used in the model are reported in Table 3 .In the model , patients receiving pazopanib were assumed to incur the cost of a 28-day supply of pazopanib each 28-day cycle if they remained alive and progression - free .", "label": "", "metadata": {}, "score": "71.973755"}
{"text": "Venous blood samples were obtained for pharmacokinetic analysis .The breast was removed surgically 2 - 5 days post administration and the treated ducts were marked to enable  it from other anti - cancer drugs .", "label": "", "metadata": {}, "score": "72.028595"}
{"text": "Objective Response Rate ( ORR ) - Independent Radiologist Review [ Time Frame : From the date of randomization until the date of disease progression or death , as assessed for approximately 3 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "72.13424"}
{"text": "PubMed ] .Bramwell VHC , Morris D , Ernst DS , Hings I , Blackstein M , Venner PM , Ette EI , Harding MW , Waxman A , Demetri GD .", "label": "", "metadata": {}, "score": "72.14142"}
{"text": "Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg / m2 in combination with PLD at 50 mg / m2 , intravenously day 1 in every 28 day cycles until tumor progression or unacceptable toxicities .", "label": "", "metadata": {}, "score": "72.185135"}
{"text": "Surgery , often combined with radiation therapy , offers the only potential cure for localized STS ; however , approximately one - half of all patients with STS eventually develop local recurrence or metastases following surgery , radiotherapy , or both [ 4 , 5 ] .", "label": "", "metadata": {}, "score": "72.527245"}
{"text": "This method is hopeful to be developed as a chemoprevention approach in patients with pre - malignant or non - invasive ductal lesions to prevent breast cancer which will be further developed .", "label": "", "metadata": {}, "score": "72.55356"}
{"text": "DOXIL will be administered over 90 minutes every 4 weeks when administered alone ( monotherapy ) and every 3 weeks when administered with trabectedin .Other Name : CAELYX .", "label": "", "metadata": {}, "score": "72.58113"}
{"text": "Reporting Groups .Description .Vemurafenib 960 mg .Patients received vemurafenib 960 mg ( four 240 mg tablets ) bid ( bis in die , twice daily ) orally until disease progression , unacceptable toxicity , withdrawal of consent , or another reason as determined by the investigator .", "label": "", "metadata": {}, "score": "72.592865"}
{"text": "Objective .To compare the tolerability , efficacy , and safety profiles of pegylated liposomal doxorubicin in combination with carboplatin ( PLD - Carbo ) with those of gemcitabine - carboplatin ( Gem - Carbo ) for the treatment of patients with platinum - sensitive recurrent ovarian cancer ( PSROC ) by reviewing the published literature .", "label": "", "metadata": {}, "score": "72.60683"}
{"text": "All AEs were assumed to require one additional consultant visit , the cost of which was based on the NHS reference costs for HRG 800 \" Clinical Oncology , Consultant Led : Follow up Attendance Non - Admitted Face to Face \" [ 35 ] .", "label": "", "metadata": {}, "score": "72.65523"}
{"text": "Fayers P , Aaronson N , Bjordal K , et al : EORTC QLQ - C30 Scoring Manual ( ed 3 ) .Brussels , Belgium , European Organisation for Research and Treatment of Cancer , 2001 17 .", "label": "", "metadata": {}, "score": "72.68137"}
{"text": "In order to provide a robust assessment of the available evidence , a systematic review was undertaken to identify , describe and interpret the current state of evidence .", "label": "", "metadata": {}, "score": "72.75274"}
{"text": "Acknowledgments .Funding for this study was provided to Policy Analysis Inc. by GlaxoSmithKline ( GSK ) .All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors .", "label": "", "metadata": {}, "score": "72.75844"}
{"text": "Includes whether analysis was per protocol , intention to treat , or another method .Also provides relevant details such as imputation technique , as appropriate .", "label": "", "metadata": {}, "score": "72.952896"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00113607 .Ovarian Neoplasms Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Genital Diseases , Female Genital Neoplasms , Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Urogenital Neoplasms BB 1101 Dexamethasone Dexamethasone 21-phosphate Dexamethasone acetate .", "label": "", "metadata": {}, "score": "72.97916"}
{"text": "PubMed ] .Brain EGC .Safety and efficacy of ET-743 : The French experience .Anti -Cancer Drugs .2002 ; 13 : S11-S14 .", "label": "", "metadata": {}, "score": "73.0007"}
{"text": "All these requirements may be best met by a concerted effort to create collaborative care between adult and paediatric experts in bone sarcoma , working together to meet TYA patients ' needs .", "label": "", "metadata": {}, "score": "73.06683"}
{"text": "Model Inputs and Parameters .Conflict of Interests .Jordan Amdahl and Thomas E. Delea are employees of PAI , which has received research funding and consulting fees from GlaxoSmithKline ( GSK ) for activities related to this study , and received support for travel to meetings to present the study results .", "label": "", "metadata": {}, "score": "73.168976"}
{"text": "23 , no .10 , pp .2763 - 2770 , 2012 .View at Publisher \u00b7 View at Google Scholar .US Food and Drug Administration , \" Votrient ( pazopanib ) tablets : for treatment of patients with soft tissue sarcoma , \" FDA Oncologic Drugs Advisory Committee Briefing Document ( NDA 22 - 465 ) , 2012 .", "label": "", "metadata": {}, "score": "73.19165"}
{"text": "J Clin Oncol .[PubMed ] .Hensley ML , Blessing JA , Degeest K , Abulafia O , Rose PG , Homesley HD .", "label": "", "metadata": {}, "score": "73.1968"}
{"text": "For this analysis , the partitioned - survival analysis modeling approach was employed ( i.e. , the model took as inputs the distribution of OS rather than the distribution of PPS ) .", "label": "", "metadata": {}, "score": "73.48216"}
{"text": "Conclusion .Results from this systematic analysis of peer - reviewed literature suggest that PLD - Carbo therapy is a rational alternative to Gem - Carbo for the treatment of patients with PSROC .", "label": "", "metadata": {}, "score": "73.84933"}
{"text": "[PubMed ] .Verweij J , Lee SM , Ruka W , Buesa J , Coleman R , van HR , Seynaeve C , di Paola ED , Van GM , Tonelli D , Judson IR .", "label": "", "metadata": {}, "score": "73.94181"}
{"text": "TheperceptionofoptimalEGFRTKIplacementinthetreatment algorithmsforNSCLChasevolvedoverthelastdecade .Gefitiniband erlotinibwereinitiallyconsideredsalvagetherapies , withlowresponse ratesbutmarginalimprovementinsurvivalcomparedwithplaceboin unselectedpatients.19,20Oncethequalitativedifferenceinresponseto EGFRTKIsamongEGFR - mutantpatientswasappreciated , random- ized studies were performed in Asian patients comparing gefitinib or erlotinibwithtaxane - andgemcitabine - basedchemotherapy.2 - 5These showed remarkable PFS improvement , but questions as to whether benefit was restricted to Asian patients arose .", "label": "", "metadata": {}, "score": "74.19098"}
{"text": "Given the small differences and inherent uncertainty associated with these comparisons , no firm conclusion can be drawn with respect to the relative cost - effectiveness of pazopanib versus these treatments .", "label": "", "metadata": {}, "score": "74.19949"}
{"text": "Ann Oncol .[PubMed ] .Sarcoma .[ PMC free article ] [ PubMed ] .Van Hoesel QG , Verweij J , Catimel G , Clavel M , Kerbrat P , Van Oosterom AT , Kerger J , Tursz T , Van GM , van PC .", "label": "", "metadata": {}, "score": "74.26869"}
{"text": "No . %No .Events were included if reported in ? 10 % of patients in either treatment group and if there was ? 10 % difference between the groups .", "label": "", "metadata": {}, "score": "74.456604"}
{"text": "PubMed ] .Bertuzzi A. Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline - based chemotherapy .J Clin Oncol .", "label": "", "metadata": {}, "score": "74.58644"}
{"text": "Description .Vemurafenib 960 mg .Patients received vemurafenib 960 mg ( four 240 mg tablets ) bid ( bis in die , twice daily ) orally until disease progression , unacceptable toxicity , withdrawal of consent , or another reason as determined by the investigator .", "label": "", "metadata": {}, "score": "74.7719"}
{"text": "PZ and NBa : Contributed to the concept and funding of the study , and reviewed the final version of the Ms. All authors reviewed and approved the final version of the article .", "label": "", "metadata": {}, "score": "74.85072"}
{"text": "Studies exclusively enrolling patients with gastrointestinal stromal tumours ( GIST ) , Kaposi sarcoma , and Ewing 's family of tumours were also excluded because of their unique biology and management compared with other STS subtypes .", "label": "", "metadata": {}, "score": "75.03634"}
{"text": "[PubMed ] .Losa R , Fra J , Lopez - Pousa A , Sierra M , Goitia A , Una E , Nadal R , Del Muro JG , Gion M , Maurel J , Escudero P , Esteban E , Buesa JM .", "label": "", "metadata": {}, "score": "75.0385"}
{"text": "Blinding : Were the care providers , participants and outcome assessors blind to treatment allocation ?Follow - up : Were there any unexpected imbalances in drop - outs between groups ?", "label": "", "metadata": {}, "score": "75.139015"}
{"text": "Drug : Dexamethasone .Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion .Active Comparator : DOXIL .Monotherapy arm - DOXIL : 50 mg / m2 IV infusion over 90 minutes every 4 weeks .", "label": "", "metadata": {}, "score": "75.1635"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Background Afatinib has shown long progression free survival and improvement in quality of life in advanced Non - Small Cell Lung Cancer ( NSCLC ) patients .", "label": "", "metadata": {}, "score": "75.27896"}
{"text": "[PubMed ] .Maki RG , Wathen JK , Patel SR , Priebat DA , Okuno SH , Samuels B , Fanucchi M , Harmon DC , Schuetze SM , Reinke D , Thall PF , Benjamin RS , Baker LH , Hensley ML .", "label": "", "metadata": {}, "score": "75.29017"}
{"text": "Lancet Oncol 13:528 - 538 , 2012 31 .Fallowfield LJ , Fleissig A : The value of progression - free survival to patients with advanced- stage cancer .", "label": "", "metadata": {}, "score": "75.301025"}
{"text": "The European Organization for Research and Treatment of Cancer [ EORTC ] , Soft Tissue and Bone Sarcoma Group .Cancer Chemother Pharmacol .1993 ; 31 : S180-S184 .", "label": "", "metadata": {}, "score": "75.59106"}
{"text": "These are not widely recognized and can cause treatment failure .PMCID : PMC3737021 PMID : 23899130 .Trabectedin related rhabdomyolysis ; Liposarcomas ; Drug - drug interactions ; Chokeberry ( Aronia melanocarpa)-drugs interaction Cost - Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom . 1 Policy Analysis Inc. ( PAI ) , Four Davis Court , Brookline , MA 02445 , USA . 2 GlaxoSmithKline , Stockley Park West , Uxbridge , Middlesex UB11 1BT , UK .", "label": "", "metadata": {}, "score": "75.71109"}
{"text": "Quantitative data synthesis .There was considerable heterogeneity across studies in terms of interventions , comparisons , patient population , and study designs .Further , the available evidence base was limited with no more than one study directly comparing the same set of interventions .", "label": "", "metadata": {}, "score": "75.78656"}
{"text": "PubMed ] .Hensley ML , Maki R , Venkatraman E , Geller G , Lovegren M , Aghajanian C , Sabbatini P , Tong W , Barakat R , Spriggs DR .", "label": "", "metadata": {}, "score": "75.8613"}
{"text": "In addition , this small - sized study was not a true RCT [ 28 ] .In terms of the patient population recruited across these studies , leiomyoscaroma was the most commonly enrolled subtype of STS followed by liposarcoma and undifferentiated pleomorphic sarcoma .", "label": "", "metadata": {}, "score": "76.06958"}
{"text": "Patients receiving gemcitabine plus docetaxel were assumed to receive treatment with lenograstim to prevent neutropenic complications ; those with prior pelvic irradiation were assumed to receive a 25 % dose reduction of gemcitabine plus docetaxel [ 33 ] .", "label": "", "metadata": {}, "score": "76.23271"}
{"text": "[PubMed ] .A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group .Eur J Cancer .[PubMed ] .", "label": "", "metadata": {}, "score": "76.38399"}
{"text": "During Treatment in Comparison to Baseline [ Time Frame : From first treatment through September 27 , 2010 ] Panobinostat Combination Delays Disease Progression in Myeloma . 1 Novartis , which manufactures panobinostat , reported that based on the PANORAMA 1 data , the FDA has granted a priority review to the drug .", "label": "", "metadata": {}, "score": "76.80144"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : To evaluate the role of enbloc resection on the oncological outcome of patients with Ewing 's sarcoma of the mobile spine treated with systemic multiagent chemotherapy combined with radiation therapy .", "label": "", "metadata": {}, "score": "77.68686"}
{"text": "Other STS - related direct medical costs were estimated based on a retrospective study of the cost of the management of metastatic STS in the UK by Judson and colleagues [ 36 ] .", "label": "", "metadata": {}, "score": "77.80029"}
{"text": "So [ this is a ] very positive study , a very important study . \"Novartis announced that additional results from PANORAMA 1 will be presented at future medical meetings this year , including an oral presentation at the 19th Congress of the European Hematology Association in June .", "label": "", "metadata": {}, "score": "77.933235"}
{"text": "Pazopanib may not be cost - effective versus placebo but may be cost - effective versus the most commonly used active treatments , although this conclusion is uncertain .", "label": "", "metadata": {}, "score": "77.94327"}
{"text": "PANORAMA 1 had two treatment phases .Patients received 20 mg of oral dexamethasone on the same day and the day after bortezomib treatment .Patients in each arm benefiting from the treatment could proceed to the second stage of the study .", "label": "", "metadata": {}, "score": "78.029526"}
{"text": "Cormier JN , Pollock RE .Soft tissue sarcomas .CA Cancer J Clin .[PubMed ] .Jain A , Sajeevan KV , Babu KG , Lakshmaiah KC .", "label": "", "metadata": {}, "score": "78.12872"}
{"text": "STS occurs rarely and accounts for approximately 1 % of malignancies in adults and 2 % of cancer mortality [ 2 , 3 ] .Nearly half of the patients diagnosed with STS develop advanced / metastatic disease and eventually die from the disease [ 4 ] .", "label": "", "metadata": {}, "score": "78.18057"}
{"text": "Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "78.23418"}
{"text": "Based on cost - effectiveness criteria used by the National Institute for Health and Care Excellence ( NICE ) , the results of our analysis suggest pazopanib is not cost - effective compared with placebo or BSC in these patients from a UK healthcare system perspective [ 39 ] .", "label": "", "metadata": {}, "score": "78.52648"}
{"text": "PAI and YHEC also received consulting fees and research funding from GSK for activities unrelated to this study .Stephanie C. Manson , Robert Isbell , and Jose Diaz are employees of and own stock in GSK , who funded this study .", "label": "", "metadata": {}, "score": "78.553444"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .Official Title : .", "label": "", "metadata": {}, "score": "78.629555"}
{"text": "Phase II trial of pegylated - liposomal doxorubicin ( Doxil(trademark ) ) in sarcoma .Cancer Invest .[PubMed ] .Toma S , Tucci A , Villani G , Carteni G , Spadini N , Palumbo R. Liposomal doxorubicin ( Caelyx ) in advanced pretreated soft tissue sarcomas : A phase II study of the Italian Sarcoma Group ( ISG )", "label": "", "metadata": {}, "score": "78.7216"}
{"text": "4 , pp .iv132-iv136 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .The ESMO / European Sarcoma Network Working Group , \" Soft tissue and visceral sarcomas : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow - up , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "79.11557"}
{"text": "Morgan JA , Le Cesne A , Chawla S , von Mehren M , Schuetze S , Casali PG , Nieto A , Elsayed Y , Izquierdo MA , Demetri GD .", "label": "", "metadata": {}, "score": "79.20079"}
{"text": "Descriptive analysis and statistics .Baseline demographics and clinical outcome statistical analyses were based on all data available up to the cut - off date of December , 31 st 2011 .", "label": "", "metadata": {}, "score": "79.3997"}
{"text": "The primary objective of this study was to evaluate the cost - effectiveness of pazopanib versus best supportive care ( BSC ) from a UK healthcare system perspective when used in patients with aSTS who have received prior anthracycline - based chemotherapy .", "label": "", "metadata": {}, "score": "79.52211"}
{"text": "Authors ' contribution .JYB : conceived the study , contributed to case collection , performed the analysis , the interpretation and wrote the primary version of the manuscript .", "label": "", "metadata": {}, "score": "79.5965"}
{"text": "Conclusions In this setting of high - risk STS treated by preoperative CT or CT - RT , the negative impact of positive margins on the outcome was limited .", "label": "", "metadata": {}, "score": "79.713646"}
{"text": "No other uses without permission .Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .Page 6 .Cisplatin plus pemetrexed is widely considered the optimal chemotherapy doublet for patients with nonsquamous NSCLC .", "label": "", "metadata": {}, "score": "80.06517"}
{"text": "[ PMC free article ] [ PubMed ] .Moher D , Liberati A , Tetzlaff J , Altman DG .Preferred reporting items for systematic reviews and meta - analyses : the PRISMA statement .", "label": "", "metadata": {}, "score": "80.13438"}
{"text": "The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum - based chemotherapy .Despite the high response rate to primary therapy , approximately 85 % of patients will develop recurrent ovarian cancer ( ROC ) .", "label": "", "metadata": {}, "score": "80.16246"}
{"text": "[ PMC free article ] [ PubMed ] .Casali PG , Blay JY .Soft tissue sarcomas : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow - up .", "label": "", "metadata": {}, "score": "80.18567"}
{"text": "ALC : contributed to case collection , contributed to the interpretation and contributed to the writing of the manuscript .FD , MR , OC , FB , FB , EB , NI , LC , PC , BNB , GD , OD , AI and NP : contributed to case collection , and contributed to the writing of the manuscript .", "label": "", "metadata": {}, "score": "80.692"}
{"text": "Ann Oncol .[PubMed ] .Patel SR , Vadhan - Raj S , Papadopolous N , Plager C , Burgess MA , Hays C , Benjamin RS .", "label": "", "metadata": {}, "score": "81.076866"}
{"text": "Dosages for PTACTs were based on published studies and prescribing information .Medication unit costs were obtained from the 63rd edition of the British National Formulary ( details on drug and administration costs are listed in Table 4 ) [ 32 ] .", "label": "", "metadata": {}, "score": "81.408226"}
{"text": "Ann Oncol .[PubMed ] .Verweij J. Docetaxel : An interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas .", "label": "", "metadata": {}, "score": "81.752884"}
{"text": "Introduction .Soft tissue sarcomas ( STS ) are a rare group of solid tumors originating from mesenchymal cells and their precursors .STS includes more than 50 histological subtypes but accounts for less than 1 % of all new malignancies in adults and approximately 2 % of total cancer - related mortality [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "82.1411"}
{"text": "Key Differences Between Regulatory and Academic Analyses of PALETTE Study .This file highlights the similarities and differences between the two different analyses ( regulatory and academic ) performed on the PALETTE data .", "label": "", "metadata": {}, "score": "82.42257"}
{"text": "In particular , STS is an ultra - rare , incurable disease with short life expectancy and for which existing therapies are inadequate .Pazopanib represents a novel therapeutic class for the treatment of this condition .", "label": "", "metadata": {}, "score": "82.80698"}
{"text": "Therefore , we used OS data as observed and included the estimated costs of PTACT in each group .While this approach is internally consistent with respect to estimates of effectiveness and costs , it may not be generalizable to other settings , where treatment with placebo followed by PTACT is not a widely used treatment strategy .", "label": "", "metadata": {}, "score": "82.83093"}
{"text": "NP declares no competing interests .Authors ' contributions .NP : helped to draft the manuscript .All authors read and approved the final manuscript .", "label": "", "metadata": {}, "score": "82.85563"}
{"text": "Anyway , a medical approach is the great news in the treatment of GCT .Denosumab is a fully human monoclonal antibody that inhibits RANKL , a protein essential for osteoclast formation , function , and survival .", "label": "", "metadata": {}, "score": "83.14615"}
{"text": "High - dose therapy added to the VACA - IE regimen in PR patients is feasible and effective .Selected groups of patients with ES can benefit from HDT .", "label": "", "metadata": {}, "score": "83.38125"}
{"text": "Costs were from published sources .Pazopanib is estimated to increase QALYs by 0.128 and costs by \u00a3 7,976 versus placebo ; cost per QALY gained with pazopanib versus placebo is estimated to be \u00a3 62,000 .", "label": "", "metadata": {}, "score": "83.7401"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Background : At diagnosis , identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma ( EWS ) patients .", "label": "", "metadata": {}, "score": "84.38721"}
{"text": "He had not received any drugs during treatment with trabectedin , but upon further questioning the patient informed us he had been taking a folk medicine preparation of chokeberry ( Aronia melanocarpa ) daily during the last course of trabectedin and in the 2 subsequent weeks .", "label": "", "metadata": {}, "score": "84.473755"}
{"text": "[PubMed ] .Grimer R , Judson I , Peake D , Seddon B. Guidelines for the management of soft tissue sarcomas .Sarcoma .", "label": "", "metadata": {}, "score": "85.03498"}
{"text": "Searching .The review was based on a comprehensive search of MEDLINE \u00ae , including MEDLINE \u00ae In - Process , Embase \u00ae , Cochrane Central Register of Controlled Trials ( CENTRAL ) , and Cochrane Database of Systematic Reviews from 1980 to 01 March 2012 .", "label": "", "metadata": {}, "score": "85.123886"}
{"text": "Chicago / Turabian Style .Schmitt , Thomas ; Keller , Eva ; Dietrich , Sascha ; Wuchter , Patrick ; Ho , Anthony D. ; Egerer , Gerlinde .", "label": "", "metadata": {}, "score": "85.343"}
{"text": "Sequist et al 3330 \u00a9 2013 by American Society of Clinical Oncology Downloaded from jco.ascopubs.org on November 5 , 2015 .For personal use only .", "label": "", "metadata": {}, "score": "85.72952"}
{"text": "Sequist et al 3332 \u00a9 2013 by American Society of Clinical Oncology Downloaded from jco.ascopubs.org on November 5 , 2015 .For personal use only .", "label": "", "metadata": {}, "score": "86.7267"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Malignant peripheral nerve sheath tumours ( MPNST ) are rare sarcomas with one of the poorest prognoses of all the soft tissue sarcomas .", "label": "", "metadata": {}, "score": "86.75459"}
{"text": "Acknowledgment Presentedatthe48thAnnualMeetingoftheAmericanSocietyofClinicalOncology , Chicago , IL , June1 - 5,2012 .Wegratefullyacknowledgethepatients , theirfamilies , andtheircaregiversforparticipationinthisstudyandthankSuzannePatelofOgilvy HealthworldMedicalEducationforeditorialsupport .Appendix MembersoftheLUX - Lung3studygroupwereasfollows : Coordinatinginvestigators : JamesChih - HsinYang , LeciaSequist .", "label": "", "metadata": {}, "score": "86.96249"}
{"text": "Clinical perspective .The primary aim of second and later line treatment of patients with advanced / metastatic soft tissue sarcoma is to delay disease progression and maintain quality of life for as long as possible .", "label": "", "metadata": {}, "score": "87.028366"}
{"text": "5 , pp .1091 - 1096 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .National Institute for Health and Care Excellence ( NICE ) , \" Tabectedin patient access scheme submission , \" Technology Appraisals , National Institute for Health and Care Excellence ( NICE ) , PharmaMar , 2009 .", "label": "", "metadata": {}, "score": "87.08056"}
{"text": "[ PMC free article ] [ PubMed ] .Skubitz KM .A phase I study of ambulatory continuous infusion paclitaxel .Anti -Cancer Drugs .", "label": "", "metadata": {}, "score": "87.665306"}
{"text": "24 , pp .5484 - 5492 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .23 , no . 3 , pp .", "label": "", "metadata": {}, "score": "87.693726"}
{"text": "4 , p. 988 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .38 , no .18 , pp .", "label": "", "metadata": {}, "score": "90.334755"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Teenagers and young adults ( TYA ) cancer contributes substantially to morbidity and mortality in a population with much to offer society .", "label": "", "metadata": {}, "score": "90.82109"}
{"text": "Competing interests .SS and ST are employees of HERON Health Pvt . Ltd. , which was commissioned by GSK to undertake the research for this review .", "label": "", "metadata": {}, "score": "91.1933"}
{"text": "Soft tissue sarcoma ( STS ) constitutes a heterogeneous group of rare cancers , with heterogeneous clinical presentation , histological subtypes and molecular alterations [ 1 ] .", "label": "", "metadata": {}, "score": "91.19427"}
{"text": "Soft tissue sarcoma accounts for less than 1 % of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes .", "label": "", "metadata": {}, "score": "91.88313"}
{"text": "View at Publisher \u00b7 View at Google Scholar .J. D. Kalbfleisch and R. L. Prentice , The Statistical Analysis of Failure Time Data , Wiley , New York , NY , USA , 1980 .", "label": "", "metadata": {}, "score": "92.68749"}
{"text": "We thank Robert Isbell and Luis Javier Hernandez Pastor who reviewed and provided feedback on the content of the manuscript .This work and the resulting publication have been funded by GSK .", "label": "", "metadata": {}, "score": "92.93285"}
{"text": "Bone tumours such as osteosarcoma and Ewing sarcoma , because of their age at presentation and the complexity of their care , are where challenges in managing ( TYA ) with cancer have often been most readily apparent .", "label": "", "metadata": {}, "score": "93.07799"}
{"text": "Keywords : Systematic review , Pazopanib , Soft tissue sarcoma .Background .Soft tissue sarcomas ( STS ) are a heterogeneous group of rare tumours that arise predominantly from the embryonic mesoderm [ 1 ] .", "label": "", "metadata": {}, "score": "93.192474"}
{"text": "Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .JOURNAL OF CLINICAL ONCOLOGY .Page 7 . a standard regimen in the United States,33bevacizumab use is not standardaroundtheworld;similarly , theadditionofbevacizumab to cisplatin and pemetrexed is not a current standard regimen .", "label": "", "metadata": {}, "score": "93.34215"}
{"text": "The primary toxicities of the drug included diarrhoea and rash .\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Objectives : Uterine serous carcinoma ( USC ) represents an aggressive variant of endometrial cancer and accounts for a large proportion of deaths annually .", "label": "", "metadata": {}, "score": "93.97148"}
{"text": "Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .Page 2 . drugintheregimen .Recently , pemetrexedhasbecomeapreferential drug for patients with lung adenocarcinoma ; randomized trials have shownityieldsfavorableresponsesandsurvivalwithbettertolerability compared with taxanes and gemcitabine in those with non-", "label": "", "metadata": {}, "score": "94.151825"}
{"text": "Although utilities from vignettes studies have been used in numerous prior cost - effectiveness analyses of oncology therapies , the validity of the values obtained from such studies has never been formally assessed .", "label": "", "metadata": {}, "score": "94.26986"}
{"text": "Indian J Cancer .[PubMed ] .Weiss SW , Goldblum JR .In : Enzinger and Weiss 's Soft Tissue Tumors .Weiss SW , Goldblum JR , editor .", "label": "", "metadata": {}, "score": "94.37491"}
{"text": "Soft tissue sarcoma ( STS ) comprises a large variety of rare malignant tumors .Development of distant metastasis is frequent , even in patients undergoing initial curative surgery .", "label": "", "metadata": {}, "score": "94.74868"}
{"text": "Soft tissue sarcoma ( STS ) comprises a large variety of rare malignant tumors .Development of distant metastasis is frequent , even in patients undergoing initial curative surgery .", "label": "", "metadata": {}, "score": "94.74868"}
{"text": "Sequist et al \u00a9 2013 by American Society of Clinical Oncology Downloaded from jco.ascopubs.org on November 5 , 2015 .For personal use only .No other uses without permission .", "label": "", "metadata": {}, "score": "96.39488"}
{"text": "Sex Male Female Age , years Median Range Race White East Asian Other Smoking status Never Former Current ECOG PS 0 1 2 Adenocarcinoma stage ?", "label": "", "metadata": {}, "score": "96.594826"}
{"text": "New drugs employed successfully in advanced mpNSt should be employed also in the adjuvant setting .Full - text \u00b7 Article \u00b7 Jan 2011 \u00b7 Journal of chemotherapy ( Florence , Italy ) .", "label": "", "metadata": {}, "score": "97.08096"}
{"text": "Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .JOURNAL OF CLINICAL ONCOLOGY .Page 5 . analysis , any events reported by investigators that were nonevents by independent review were censored at the time of discrepancy ; there- fore , thetruetreatmenteffectcouldhavebeenunderestimated , aswas shown in several preplanned sensitivity and subgroup analyses using investigator - generatedprogressionevents .", "label": "", "metadata": {}, "score": "97.610374"}
{"text": "PubMed View Article .Pre - publication history .Copyright .\u00a9 Blay et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. all Addendum Article Book Review Case Report Comment Commentary Communication Concept Paper Conference Report Correction Creative Data Descriptor Discussion Editorial Erratum Essay Interesting Images Letter New Book Received Obituary Opinion Project Report Reply Retraction Review Short Note Technical Note .", "label": "", "metadata": {}, "score": "98.17528"}
{"text": "187 - 200 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .View at Google Scholar .91 , no .", "label": "", "metadata": {}, "score": "98.89335"}
{"text": "SEPTEMBER 20 2013 \u00a9 2013 by American Society of Clinical Oncology 3327 Downloaded from jco.ascopubs.org on November 5 , 2015 .For personal use only .", "label": "", "metadata": {}, "score": "99.76842"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "104.85021"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Giant cell tumor ( GCT ) of bone is an aggressive neoplasm arising from the medullary and consisting of multinucleated osteoclast - like giant cells and proliferating osteoblast - like stromal cells .", "label": "", "metadata": {}, "score": "105.22073"}
{"text": "British National Formulary ( BNF ) 63 , British Medical Journal Publishing Group and Pharmaceutical Press , 2012 .17 , no . 9 , pp .", "label": "", "metadata": {}, "score": "105.318115"}
{"text": "View at Publisher \u00b7 View at Google Scholar .L. Curtis , Unit Costs of Health and Social Care 2010 , University of Kent , 2010 .", "label": "", "metadata": {}, "score": "106.425156"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .109 , no . 3 , pp .323 - 328 , 2008 .", "label": "", "metadata": {}, "score": "109.783905"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .27 , no .25 , pp .4188 - 4196 , 2009 .", "label": "", "metadata": {}, "score": "110.74924"}
{"text": "4 University of Toronto , 144 College Street , Toronto , ON , Canada M5S 3M2 .5 York Health Economics Consortium , Level 2 , Market Square , University of York , Heslington , York YO10 5NH , UK .", "label": "", "metadata": {}, "score": "115.44142"}
{"text": "Patient disposition .For personal use only .No other uses without permission .Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .", "label": "", "metadata": {}, "score": "120.872475"}
{"text": "Academic Editor : Antoine Italiano .Copyright \u00a9 2014 Jordan Amdahl et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "124.32694"}
{"text": "No other uses without permission .Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .JOURNAL OF CLINICAL ONCOLOGY .Page 3 .", "label": "", "metadata": {}, "score": "125.79118"}
{"text": "For personal use only .No other uses without permission .Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .Page 8 .", "label": "", "metadata": {}, "score": "127.693985"}
{"text": "For personal use only .No other uses without permission .Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .Page 10 .", "label": "", "metadata": {}, "score": "129.4563"}
{"text": "All rights reserved .JOURNAL OF CLINICAL ONCOLOGY .Page 11 .For personal use only .No other uses without permission .Copyright \u00a9 2013 American Society of Clinical Oncology .", "label": "", "metadata": {}, "score": "130.21078"}
{"text": "For personal use only .No other uses without permission .Copyright \u00a9 2013 American Society of Clinical Oncology .All rights reserved .JOURNAL OF CLINICAL ONCOLOGY .", "label": "", "metadata": {}, "score": "131.83011"}
